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1 INTRODUCTION 
Myeloproliferative diseases (MPDs) or neoplasms (MPNs) represent a heterogeneous 
group of clonal haematopoietic stem cell (HSC) disorders characterized phenotypically by an 
abnormal accumulation of mature-appearing myeloid cells of one or more lineages [1]. The 
so-called “classic” MPDs – now referred to as “classic” MPNs – include chronic myeloid 
leukaemia (CML), polycythaemia vera (PV), essential thrombocythaemia (ET), and primary 
myelofibrosis (PMF) [2]. The Polycythaemia Vera Study Group (PVSG) and the World 
Health Organization (WHO) classifications distinguish the Philadelphia chromosome (Ph)-
positive CML from the Ph-negative entities ET, PV, and PMF [3]. 
Following the discovery of the disease-causing BCR–ABL1 mutation in CML, a 
number of other fusion genes and oncogenic tyrosine kinase mutations such as Fip1-like-1–
platelet-derived growth factor receptor alpha gene fusion (FIP1L1–PDGFRA) as well as Kit 
(KIT D816V ) and Janus kinase 2 (JAK2 V617F) mutations have also been identified [4]. The 
2008 WHO classification of myeloid neoplasms and acute leukaemia incorporating this new 
knowledge provides a novel, morphology-, cytogenetics-, and molecular diagnostics-based 
nomenclature and classification of MPDs [5]. 
In this revised classification, the expression “myeloproliferative disorder” has been 
replaced by “myeloproliferative neoplasm”. In addition to changes in the nomenclature, a 
significant modification was – based on their shared features – the enrolment of mast cell 
diseases (MCDs) among MPNs and the re-organization of chronic eosinophilic 
leukaemia/hypereosinophilic syndrome (CEL/HES) into “CEL, not otherwise specified 
(CEL-NOS)” as well as “myeloid and lymphoid neoplasms associated with eosinophilia and 
abnormalities of PDGFRA, platelet-derived growth factor receptor beta (PDGFRB), or 
fibroblast growth factor receptor 1 (FGFR1)” (Table 1) [5].  
Eight clinicopathological entities fall therefore currently under the category of MPNs: 
BCR–ABL1-positive CML and seven BCR–ABL1-negative conditions including chronic 
neutrophilic leukaemia, PV, PMF, ET, CEL-NOS, mastocytosis, and MPNs – unclassifiable 
[6]. The term “Ph-negative MPNs” is still widely used as a synonym for classic BCR–ABL1-
negative MPNs (PV, ET, PMF) and, in the broader sense, also for other BCRABL1-negative 
myeloproliferative conditions such as certain rare entities like HES or systemic mastocytosis 
(SM).  
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Table 1. Classification of myeloid neoplasms according to the 2008 WHO scheme [5] 
1. Myeloproliferative neoplasms (MPNs) 
1.1. Chronic myeloid leukaemia (CML), BCR–ABL1-positive 
1.2. Polycythaemia vera (PV) 
1.3. Essential thrombocythaemia (ET) 
1.4. Primary myelofibrosis (PMF) 
1.5. Chronic neutrophilic leukaemia (CNL) 
1.6. Chronic eosinophilic leukaemia, not otherwise specified (CEL-NOS) 
1.7. Mast cell disease (MCD) 
1.8. MPN, unclassifiable 
2. Myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, 
PDGFRB, or FGFR1 
3. Myelodysplastic/myeloproliferative neoplasms (MDSs/MPNs) 
3.1. Chronic myelomonocytic leukaemia (CMML) 
3.2. Juvenile myelomonocytic leukaemia (JMML) 
3.3. Atypical chronic myeloid leukaemia, BCR–ABL1-negative (aCML) 
3.4. MDS/MPN, unclassifiable 
4. Myelodysplastic syndromes (MDSs) 
5. Acute myeloid leukaemia (AML) 
FGFR1, fibroblast growth factor receptor 1; PDGFRA, platelet-derived growth factor receptor alpha; PDGFRB, 
platelet-derived growth factor receptor beta. 
 
Polycythaemia vera (PV) is the most common entity among all Ph-negative 
myeloproliferative disorders which, due to its vascular complications, represents an 
interdisciplinary significance. PV is characterized by the trilineage clonal proliferation of 
HSC-derived haematopoietic progenitors resulting in the expansion of the erythrocyte mass. 
In addition to blood hyperviscosity, the increased red blood cell (RBC) mass results in a 
higher risk for thrombosis, poor quality of life, and a shorter life expectancy. PV warrants 
particular attention for the higher risk of cardiovascular (CV) and cerebrovascular events as 
leading determinants of morbidity and mortality. Predominant are arterial thrombotic events, 
in particular large vessel arterial events including cerebrovascular events, myocardial 
infarction, and peripheral arterial occlusion. PV-related haemostatic abnormalities due to 
qualitative disorders of erythrocytes, neutrophils, and platelets (PLTs) and the pathogenesis of 
the major thrombotic complications are extensively investigated yet not fully unravelled. 
From clinical and therapeutical aspects, the role and significance of additional risk factors in 
the development of PV-associated thrombotic events is of major importance – over the last 
few years, this topic has been actively investigated. 
Systemic mastocytosis (SM), an exceedingly rare of Ph-negative MPNs is considered 
as an orphan disease with less known clinical presentation, prognosis, and challenging 
treatment. The multidisciplinary significance of SM can be attributed to the pathological 
accumulation of morphologically and immunophenotypically abnormal mast cells in one or 
more organ systems. From mast cell diseases (MCDs) our research focussed on systemic 
mastocytosis (SM) due to its low incidence rate, heterogeneous manifestation, and clinical 
complexity and the diagnostic difficulties often associated with it. As the presentation of SM 
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may vary from asymptomatic to severe forms, its diagnosis can be especially challenging, 
both from a clinical and pathological perspective. Up to now, only very limited 
epidemiological data are available on SM. Although a small set of regional data have been 
collected through the European Competence Network on Mastocytosis (ECNM), no 
Hungarian data at all are present. 
Among Ph-negative MPNs, hypereosinophilic syndromes (HESs) make up the most 
heterogeneous and widely debated group of diseases. The clinical presentation of HES is 
highly variable ranging from a relatively asymptomatic disease to endomyocardial fibrosis. 
Although HES may also be associated with other organ system failures, cardiac involvement 
and in particular Loeffler’s endocarditis still remain its best known manifestation. As HES 
represents a very heterogeneous group of diseases, its definition has been strongly debated for 
decades. Thanks to the current molecular and immunological diagnostic methods, an 
aetiology-based classification in certain types of HESs is now possible, yet at the price of an 
even more complicated terminology. 
The clinical presentation of HES is highly variable ranging from a relatively 
asymptomatic disease to endomyocardial fibrosis. A well-known and frequent cardiac 
manifestation of HES is Loeffler's endocarditis [7-9]. The cardiac involvement begins with 
eosinophilic infiltration, followed by an intermediate thrombotic stage, and finally evolving 
into a late fibrotic stage [7]. Enlarged atrium with normal-sized left ventricle (LV) is a minor 
criterion for endomyocardial fibrosis. At this moment, little is known about left atrial (LA) 
function in HES. In our research, we investigated a) the ability of a novel non-invasive 
clinical tool (three-dimensional speckle tracking echocardiography, 3DSTE) to reveal any 
change in the cardiac functional parameters in a sub-type of HES considered idiopathic in its 
etiology HES (iHES) without manifest organ damage (as determined by conventional 
diagnostic methods) as well as b) the left ventricular (LV) rotational mechanics in clinically 
symptomatic Loeffler’s endocarditis. 
 This work discusses the clinical, laboratory, and molecular characteristics of selected 
Ph-negative MPNs like PV, SM, and HES and examines how heterogeneous their clinical 
appearance can be despite their common HSC-derived origin. The diagnosis and treatment of 
all three Ph-negative MPNs require a strong multidisciplinary (cardiological – neurological – 
dermatological) approach and a close co-operation with other clinical specialists.  
2 AIMS 
The aim of our research was to create a retrospective database of Ph-negative MPNs 
including three separate cohorts of patients diagnosed with PV, SM, or HES. This work 
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evaluates and analyses separately the PV, SM, and HES patient cohorts of the 2nd Department 
of Internal Medicine and Cardiology Centre, Albert Szent-Györgyi Health Centre, Faculty of 
Medicine, University of Szeged, with the following objectives in each cohort: 
 
I. PV cohort: 
Given that PV is the most common type of Ph-negative MPNs and in this group of diseases, 
vascular events are of outstanding significance and diagnostics, efficacious treatment can only 
be achieved on a multidisciplinary level, we assessed our patient population in the following 
aspects: 
a) to evaluate the incidence of thrombotic events prior to and during follow-up; and to 
investigate the main clinical characterteristics of PV patients, either with or without 
thrombotic complications in the follow-up period; 
b) to assess the major cerebrovascular and cardiac thrombotic complications as the most 
serious thrombotic complications in the PV cohort; and to investigate whether any 
typical neurological or cardiac lesion(s) could be identified which might be specific to, 
or characteristic of PV; and 
c) to evaluate the contribution of the main CV risk factors present at time of 
haematological diagnosis of PV as possible additional risk factors for subsequent 
thrombotic complications. 
 
II. SM cohort: 
Analyses in our SM patient group were driven by the orphan nature and the diagnostic, 
therapeutic, and prognostic difficulties usually associated with this condition as follows: 
a) to describe the clinicopathological findings along with bone marrow histological 
features, molecular characteristics, and laboratory parameters at presentation in a large 
cohort of SM patients;  
b) to evaluate the frequency of KIT D816V mutation in SM subgroups; 
c) to estimate the life expectancy of SM patients compared to age- and sex-matched 
controls; and to evaluate the prognostic relevance of the WHO classification of SM in 
the investigated patient population; and 
d) to quantify the cumulative incidence of SM in the South Great Plain region of 
Hungary. 
 
III. HES cohort: 
HES, a condition with highly variable clinical presentation and organ involvement also 
belongs to the group of rare Ph-negative MPNs. In this patient population the aims of our 
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investigations were:  
 
a) to compare LA volumetric, volume-based functional, and strain parameters obtained 
by three-dimensional speckle-tracking echocardiography (3DSTE), a novel, 
non-invasive clinical tool for volumetric and strain analysis, between HES patients and 
matched controls; and 
b) to demonstrate LV rotational mechanics in a unique case with Loeffler's endocarditis. 
3 PATIENTS, METHODS, AND RESULTS 
As basis for this research, we retrospectively established a database for scientific 
research, focussing especially on PV, SM, and HES cases diagnosed at the 2nd Department of 
Internal Medicine and Cardiology Centre between 1998 and 2014 (Table 2).  
 
Table 2. Overview of the main characteristics of the investigated study population 
Main characteristics 
Patient population 
PV SM HES 
Data collection period 1998–2014 2001–2013 2001–2014 
Total number of patients 108 35 11 
   Males [N (%)] 57 (52.8%) 19 (54.2%) 8 (72.7%) 
   Females [N (%)] 51 (47.2%) 16 (45.7%) 3 (27.2%) 
Median age at diagnosis (years) (range) 62.6 (24.8–82.0) 57 (31–85) 59 (33–77) 
Median follow-up (months) (range) 54 (0.0–16.1) 30.5 (1–240) 45 (2–168) 
HES, hypereosinophilic syndrome; PV, polycythaemia vera; SM, systemic mastocytosis. 
 
Our investigations were conducted with the approval of the Regional and Institutional 
Human Medical Biological Research Ethics Committee of the Albert Szent-Györgyi Health 
Centre, University of Szeged and in accordance with the Declaration of Helsinki principles. 
Written informed consent was not required from the subjects. The review of trial subjects’ 
relevant medical data was done by using MedSolution, the healthcare data management 
system of the Albert Szent-Györgyi Health Centre, Faculty of Medicine, University of 
Szeged. 
 
3.1 POLYCYTHAEMIA VERA 
3.1.1 GENERAL CONSIDERATIONS AND BACKGROUND OF THE POLYCYTHAEMIA 
VERA STUDY 
PV is generally characterized by erythrocytosis, but other signs and symptoms like 
leukocytosis, thrombocytosis, splenomegaly, vasomotor disturbances, thrombosis, bleeding, 
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or pruritus may also be present. The incidence of PV ranges in European Union from 0.4 to 
2.8 cases per 100,000 persons per year [10]. PV occurs in all populations and in all age groups 
including young adults and occasionally children and adolescents, too. The median age at 
diagnosis was around 61 years (range: 18–95 years) in a group of 1545 patients with WHO-
defined PV assessed by the International Working Group for Myeloproliferative Neoplasms 
Research and Treatment [11]. The incidence of PV was slightly higher in men than in women 
(2.8 vs. 1.3 cases per 100,000 persons per year), with the highest rates in men aged 70–
79 years (24 cases per 100,000 persons per year) [12]. 
The diagnosis of PV is based on the current WHO criteria including clinical and laboratory 
findings and the molecular analysis of JAK V617F mutation [13]. The diagnosis is established 
if both major criteria and at least one minor criterion, or the first major criterion and at least 
two minor criteria are present (Table 3). 
 
Table 3. Diagnostic criteria of polycythaemia vera [13] 
Major criteria 
1. Hb >18.5 g/dL in men, 16.5 g/dL in women, or other evidence of increased red cell volume 
2. Presence of JAK2 V617F or other functionally similar mutation such as JAK2 exon 12 
mutation 
Minor criteria 
1. Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) 
with prominent erythroid, granulocytic, and megakaryocytic proliferation 
2. Serum erythropoietin level below the reference range for normal 
3. Endogenous erythroid colony formation in vitro 
Hb, haemoglobin; JAK2, Janus kinase 2. 
 
JAK2 V617F is by far the most prevalent mutation in BCR–ABL1-negative MPNs: it occurs in 
~95% of patients with PV, in ~55% with ET, and in ~65% with PMF, respectively [6]. 
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) signalling 
pathway is of central importance in a number of cellular processes including proliferation, 
survival, and normal functioning of haematopoietic and other cells [6]. The vast majority 
(~96%) of PV patients have a JAK2 V617F somatic activating mutation in exon 14 while the 
rest of them (~3%) exhibit a JAK2 exon 12 mutation [14]. The overall median survival in PV 
is 14 years with a median survival time of 24 years for patients younger than 60 years [15]. 
The 10-year risk is 3% and 10% for leukaemic transformation and fibrotic transformation, 
respectively [16]. Leukaemic transformation rates at 20 years are estimated at <10% in PV 
[17]. 
In contrast, the risk of thrombosis in PV is high: the prevalence of major thrombotic events 
(arterial events: acute myocardial infarction [AMI], ischaemic stroke, transient ischaemic 
attack [TIA]; venous events: deep vein thrombosis [DVT], pulmonary embolism [PE], 
splanchnic thrombosis) at the time of diagnosis ranges approximately 34% to 39%; 
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corresponding values for thrombosis at follow-up are approximately 8% to 19%. Concerning 
major thrombotic events, arterial complications occur more often than venous ones. Clinical 
manifestation of these thrombotic events is mainly discussed only in isolated case reports or 
case series. A large proportion of patients suffer from vasomotor disturbances (e.g. headache, 
dizziness, erythromelalgia, acral paraesthesias, atypical chest pain) or pruritus [18]. Some 
patients may also develop acquired von Willebrand syndrome, especially those with extreme 
thrombocytosis (PLT >1,000×109/L) in both PV and ET and are at risk for acetylsalicylic acid 
(ASA)-associated bleeding [17]. Thrombosis is a leading cause of morbidity and mortality in 
PV. The pathogenesis of acquired thrombophilic state in PV is multifactorial and complex. 
Currently, two main mechanisms are considered as of crucial role: on the one hand, the 
abnormalities of blood cells (platelets, RBCs, and white blood cells [WBCs]) arising from the 
clonal proliferation of haematopoietic progenitor cells and the acquisition of a prothrombotic 
phenotype and on the other hand, the host inflammatory response to cytokines and other 
mediators secreted by the malignant cells as well as the procoagulant activity of vascular cells 
triggered by these proinflammatory stimuli [19]. Abnormalities of the clonal proliferation of 
HSCs include not only quantitative changes but also qualitative modifications that 
characterize the switch of these cells from a resting to a procoagulant phenotype [20]. 
3.1.2 STUDY POPULATION AND DATA COLLECTION 
To establish our PV database, we relied on two sources. First, we screened medical 
records (MedSolution) of patients presented at the Haematology Outpatient Unit, 
2nd Department of Internal Medicine and Cardiology Centre with the orienting diagnosis of 
different chronic MPDs, per appropriate ICD (International Classification of Diseases, 
ICD-10) codes and in a given time period; and second, we checked data of patients subject to 
molecular diagnostic testing for myeloproliferative disorders at the Department of Medical 
Genetics, Faculty of Medicine, University of Szeged. Finally, we set up an integrated 
database including the relevant elements of both data sources. 
For our research, medical records of a total of 933 patients were screened. Out of them, the 
definite diagnosis of PV fulfilling WHO criteria could be established in 108 cases. Data of 
these 108 subjects made up our “PV Database 1998–2014” (Table 4). 
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Table 4. Main demographic and clinicohaematological characteristics of the polycythaemia 
vera population 
Main characteristics of the PV cohorts Database 1998–2014 
Total number of patients 108 
   Males [N, (%)] 57 (52.8%) 
   Females [N, (%)] 51 (47.2%) 
Age at diagnosis, median (years) (range) 62.6 (24.8–82.0) 
Median follow-up (months) (range) 54 (0.0-16.1) 
Median Hb (g/L) 174.1 ± 24.0 
Median leukocyte count at diagnosis (range) (G/L) 11.2 ± 4.6 (5.2-31.8) 
Median platelet count at diagnosis (range) (G/L) 398.8 ± 232.7 (65-1329) 
JAK2 V617F-positive cases [N, (%)] 102 (94.4%) 
Conventional risk factors in PV 
   Age >60 years [N, (%)] 62 (57.4%) 
   Prior thrombotic events 33 (30.5%) 
Low risk [N, (%)] 36 (33.3%) 
High risk [N, (%)] 72 (66.7%) 
Hb, haemoglobin; JAK2, Janus kinase 2; PV, polycythaemia vera. 
 
Thrombotic events prior to and following the clinical diagnosis were retrospectively 
collected for each PV patient, with special focus on CV (AMI), cerebrovascular (stroke, TIA, 
vertebrobasilar insufficiency [VBI]), and venous thrombotic events (DVT, PE, splanchnic 
vein thrombosis). 
Data on CV risk factors present at time of PV clinical diagnosis including 
hypertension, tobacco use, diabetes mellitus (DM), hyperlipidaemia (hypercholesterolaemia 
or hypertriglyceridaemia or both), and obesity (body mass index >30 kg/m2) were also 
collected (Table 5). 
 
Table 5. Distribution of cardiovascular risk factors at time of the clinical diagnosis of 
polycythaemia vera 
Distribution of CV risk factors in PV patients [N (%)] 
Hypertension 73 (67.6%) 
Hyperlipidaemia  32 (29.6%) 
Diabetes mellitus 23 (21.3%) 
Tobacco use 21 (19.4%) 
Obesity (BMI >30 kg/m2) 30 (27.8%) 
BMI, body mass index; CV, cardiovascular; PV, polycythaemia vera. 
 
In the haematological management of PV patients, a risk-oriented strategy was 
adopted: selected low-risk patients received anti-platelet therapy while cytoreductive drugs 
(e.g. hydroxyurea) in combination with anti-platelet medication were administered to high-
risk patients. Phlebotomy was reserved for low-risk patients and for those at high risk before 
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cytoreductive treatment in order to reach the recommended target haematocrit (Hct) value of 
<0.45 (Table 6) [21]. 
 
Table 6. Haematological treatment of polycythaemia vera patients 
Haematological treatment of PV patients [N (%)] 
Phlebotomy 51 (47.2%) 
Platelet aggregation inhibitor (ASA) 79 (73.1%) 
ASA + phlebotomy 41 (38.0%) 
Cytoreductive treatment (hydroxyurea) 50 (46.3%) 
ASA, acetylsalicylic acid; PV, polycythaemia vera. 
3.1.3 STATISTICAL ANALYSES 
Clinical data were collected using Microsoft® Excel® 2010 software and subjected to 
statistical analysis with STATISTICA v9.1 (StatSoft, Hungary) and SPSS 20 (IBM, USA) 
softwares. 
 
Investigation of the contribution of cardiovascular risk factors in polycythaemia vera 
To evaluate and compare the overall effect of CV risk factors present at time of 
haematological diagnosis, Mann–Whitney U tests were performed both for the presence and 
the absence of thrombotic complications, i.e., CV (AMI), cerebrovascular (ischaemic stroke, 
TIA, VBI), and venous thrombotic events (DVT, PE, splanchnic vein thrombosis). In addition 
to each predefined CV risk factor (hypertension, hyperlipidaemia, tobacco use, DM, and 
obesity), the effect of only one CV risk factor, the effect of two or more CV risk factors as 
well as the role of leukocytosis (>11.1 G/L) or increased Hct (>45%) were also investigated. 
Statistical significance was set at 5% and, as reasoned by study population size, also 
considered at 10%. 
To evaluate and compare the probability of thrombosis-free survival for PV patients a) 
without CV risk factors and with at least one CV risk factor and b) with at most one CV risk 
factor and with two or more CV risk factors, the Kaplan–Meier method was used, combined 
with log-rank (Mantel–Cox) tests [22]. 
3.1.4 LABORATORY METHODS 
Samples for JAK2 V617F molecular analyses were obtained from the DNA bank of 
the Department of Medical Genetics based on the information on PV patients diagnosed at the 
2nd Department of Internal Medicine and Cardiology Centre between 1998 and 2014. DNA 
was isolated from ethylenediaminetetraacetic acid (EDTA) -stabilized peripheral blood 
samples and screened for JAK2 V617F mutation using allele-specific polymerase chain 
reaction (PCR) method as part of the routine diagnostic protocol [23]. For patients whose 
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haematological diagnosis was established before JAK2 V617F mutation screening had 
become an obligatory part of the diagnostic protocol, samples for genetic testing were 
collected and analyzed retrospectively. 
Serum erythropoietin levels were determined by chemiluminescent immunoassay (Siemens 
Immulite) at the Laboratory of Endocrinology, University of Szeged [24]. 
3.1.5 RESULTS 
THROMBOTIC EVENTS PRIOR TO AND DURING FOLLOW-UP AND THE MAIN CLINICAL 
CHARACTERTERISTICS OF POLYCYTHAEMIA VERA PATIENTS WITH OR WITHOUT THROMBOTIC 
COMPLICATIONS IN THE FOLLOW-UP PERIOD (Aim I.a) 
The retrospective analysis of all recorded events revealed altogether 33 pre-diagnosis vascular 
events in 108 (30.5%) patients: 17 cerebrovascular events (stroke/TIA), 8 CV events (AMI), 
and 8 venous thrombotic events. During the haematological follow-up after the diagnosis of 
PV, a total of 20 events were observed in 108 (18,5%) patients: 11 cerebrovascular events 
(stroke/TIA), 7 CV events (AMI), and 2 venous thrombotic events (Table 7).  
 
Table 7. Vascular events before the clinical diagnosis of polycythaemia vera and during 
follow-up
Type of the vascular event Number of the vascular events 
Prediagnostic major vascular events 33 
   Cerebrovascular events (stroke/TIA/VBI) 17 
   CV events (AMI) 8 
   Venous thrombotic events 8 
Follow-up 20 
   Cerebrovascular events (stroke/TIA/VBI) 11 
   CV events (AMI) 7 
   Venous thrombotic events 2 
TIA, transient ischaemic attack; VBI, vertebrobasilar insufficiency; CV, cardiovascular; AMI, acute myocardial 
infarction. 
 
We investigated whether subjects with or without a post-diagnostic history of 
thrombotic events significantly differ in their main clinical characteristics (Table 8). 
Mann–Whitney tests were performed in the cases of the presence or absence of 
thrombotic events after the diagnosis of PV, comparing the overall effects of series variables: 
mean follow-up, mean age at diagnosis, JAK2 V617F-positivity, haematology blood test 
results, organomegaly, number of thrombotic events before heamatological diagnosis, 
vascular risk factors, and treatment. Fisher’s exact test results were considered for sex and 
conventional risk groups. Some CV risk factors as hypertension (p=0.001) and tobacco use 
(p=0.023) were significantly different in our two patient groups; the different thrombotic risk 
of conventional low- and high-risk groups (p=0.029) was confirmed as well. 
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Table 8. Characteristics of polycythaemia vera patients with or without thrombotic 
complications during follow-up 
MAIN CLINICAL CHARACTERISTICS 
PATIENTS WITH 
THROMBOTIC 
COMPLICATIONS 
PATIENTS WITHOUT 
THROMBOTIC 
COMPLICATIONS 
P-VALUE 
Number of patients N=108 (100%) 18 90  
Male [N (%)] 12 (66.7%) 45 (50.0%) 
0.198 
Female [N (%)] 6 (33.3%) 45 (50.0%) 
Mean follow-up (years) 3.9 (0.1–11.1) 5.8 (0.0–23.0) 0.273 
Mean age at diagnosis (years) 64.9 (38.2–78.5) 59.8 (24.8–82.0) 0.106 
JAK2 V617F-positivity [N (%)] 16 (88.9%) 86 (95.6%) 0.256 
Haematology blood test results at time of haematological diagnosis  
Mean platelet count (G/L) 467.7 ± 274.8 385.0 ± 222.5 0.255 
Mean white blood cell count (G/L) 12.7 ± 6.1 10.9 ± 4.3  0.463 
Mean red blood cell count (T/L) 6.4 ± 0.8 6.1 ± 1.2 0.059 
Mean haemoglobin (g/L) 178.7 ± 27.4 173.1 ± 23.3 0.316 
Organomegaly at time of haematological diagnosis  
Hepatomegaly  6 (33.3%) 33 (36.7%) 0.789 
Splenomegaly  6 (33.3%) 26 (28.9%) 0.707 
Hepatosplenomegaly  2 (11.1%) 19 (21.1%) 0.330 
Number of thrombotic events  
Before heamatological diagnosis 6 27 0.937 
After heamatological diagnosis 20 0 – 
Vascular risk factors    
Hypertension 18 (100.0%) 55 (61.1%) 0.001 
Tobacco use 0 (0.0%) 21 (23.3%) 0.023 
Diabetes mellitus 5 (27.8%) 18 (20.0%) 0.464 
Obesity 8 (44.4%) 22 (24.4%) 0.085 
Hyperlipidaemia 8 (44.4%) 24 (26.7%) 0.133 
Patient distribution by conventional risk categories  
Low-risk group 2 (11.1%) 34 (37.8%) 
0.029 
High-risk group 16 (88.9%) 56 (62.2%) 
Treatment  
Hydroxyurea 10 (55.6%) 40 (44.4%) 0.390 
Acetylsalicylic acid 14 (77.8%) 65 (72.2%) 0.629 
Phlebotomy 10 (55.6%) 41 (45.6%) 0.440 
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CARDIOVASCULAR AND CEREBROVASCULAR COMPLICATIONS (Aim I.b) 
Cardiovascular complications 
Detailed clinical data and coronary angiography findings for adequate cardiological 
analyses of CV complications in PV patients during follow-up were available for 6 patients 
(1 male, 5 females; mean age 69.5 years [range: 64–76 years]). 
Mean Hct was 52.8 ± 8.6% at time of haematological diagnosis and 49.5 ± 7.9% at the 
onset of AMI. Median WBC count was 11.28 ± 5.7 G/L at haematological diagnosis while by 
the onset of AMI, it increased to a level of 13.47 ± 5.8 G/L. 
Five (83.3%) out of the six analyzed patients exhibited JAK2 V617F mutation. Most of 
the patients (83.3%) had at least two major conventional CV risk factors. 
Non–ST-segment elevation myocardial infarction (NSTEMI) was diagnosed in all six 
PV patients by coronary angiography. Significant stenosis of coronary arteries requiring 
percutaneous coronary intervention with stent implantation was seen in two patients. 
Coronary angiography showed only normal epicardial coronary arteries, non-significant 
stenosis, or distal occlusion in one patient each. One patient underwent coronary artery bypass 
grafting and saphenous vein graft stenting. Evaluated cases are listed individually in Table 9. 
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Table 9. Presentation of individual polycythaemia vera patients with cardiovascular complications enrolled in the detailed analyses 
ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; CV, cardiovascular; DM, diabetes mellitus; F, female; LAD, left anterior descending coronary artery; 
LCX, left circumflex coronary artery; LIMA, left internal mammary artery; LM, left main coronary artery; M, male; NSTEMI, non–ST-segment elevation myocardial 
infarction; OM, obtuse marginal artery; PCI, percutaneous coronary intervention; PV, polycythaemia vera; RC, right coronary artery; SVG, saphenous vein graft. 
CASE NO. 
AGE/SEX/DA
TE OF 
DIAGNOSIS 
TIME 
BETWEEN 
CARDIOLOGIC
AL EVENT AND 
PV 
DIAGNOSIS 
CV RISK 
FACTORS 
PRESENT AT PV 
DIAGNOSIS 
JAK2 V617F 
MUTATION 
CARDIOLOGICAL COMPLICATIONS 
HAEMATOLOGICAL 
TREATMENT AFTER PV 
DIAGNOSIS CARDIOLOGICAL 
PRESENTATION 
CORONARY ANGIOGRAPHY FINDINGS 
CASE 1 
72/M/2005 
8 months 
hypertension, 
hyperlipidaemia, 
obesity 
negative NSTEMI 
LAD: diagonal borderline lesion 
LCX: first OM branch 20% stenosis 
RC: ostial 80% stenosis (PCI + stent implantation) 
ASA + clopidogrel + 
phlebotomy 
CASE 2 
63/F/2010 
15 months hypertension positive NSTEMI 
LAD: proximal 90% stenosis (PCI + stent implantation) 
LCX: normal 
RC: 50% stent stenosis 
ASA + clopidogrel 
CASE 3 
74/F/2005 
41 months 
hypertension, 
hyperlipidaemia 
positive NSTEMI 
LAD: proximal 40% stenosis 
LCX: normal 
RC: normal 
Hydroxyurea + 
phlebotomy 
CASE 4 
76/F/2009 
13 months 
hypertension, 
hyperlipidaemia, 
obesity, DM 
positive NSTEMI 
LAD: ostial occlusion, LIMA-LAD (normal) 
LCX: 95% stenosis, proximal 70% stenosis of SVG-LCX 
(stent in SVG) 
RC: proximal occlusion 
(CABG) 
ASA + phlebotomy 
CASE 5 
64/F/2013 
8 months 
hypertension, 
obesity 
positive NSTEMI 
LAD: normal 
LCX: normal 
RC: normal 
ASA 
CASE 6 
68/F/2011 
4 months 
hypertension, 
obesity, DM 
positive NSTEMI 
LAD: normal 
LCX: normal 
RC: distal occlusion 
ASA + hydroxyurea 
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Cerebrovascular complications 
Detailed analysis of cerebrovascular events was performed in 11 out of the 108 PV 
patients enrolled (9 males, 2 females; median age: 65 years [range: 52–79 years]). 
JAK2 V617F mutation positivity was detected in 10 of the 11 analyzed cases (91%). Most of 
the patients (8/11, 72%) had at least two major conventional vascular risk factors (e.g. 
hypertension, hyperlipidaemia, DM, or obesity). 
Mean Hct level at onset of cerebrovascular complications after the initiation of 
specific haematological treatment was lower (45% [range: 41–57%]) than at PV 
haematological diagnosis (54% [range: 45–66%]). Mean WBC at time of haematological 
diagnosis was 13 G/L (range: 5–24 G/L) and persisted (13 G/L [range: 5–25 G/L]) during the 
course of post-treatment cerebrovascular thrombotic events. 
In most of the cases (7/11 patients, 63%), chronic ischaemic white matter lesions were 
detected on brain computed tomography scan obtained at cerebrovascular event onset. In 
addition, mild cerebral atrophy was also a frequent finding. The clinical presentation was 
predominated by lacunar syndromes or VBI. Two patients – one of them on anticoagulant 
therapy – sustained haemorrhagic stroke. Overall, these data allow us to suppose that after 
adjusting for major conventional vascular risk factors, PV predisposes to small vessel cerebral 
disease manifested mainly as lacunar syndromes, even if most of the patients had additional 
vascular risk factors, too. Evaluated cases are listed individually in Table 10. 
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Table 10. Main characteristics of polycythaemia vera patients with cerebrovascular event 
AF, atrial fibrillation; ASA, acetylsalicylic acid; CT, computed tomography; CV, cardiovascular; DM, diabetes mellitus; F, female; M, male; MCA, middle cerebral artery; 
MRI, magnetic resonance imaging; PAD, peripheral arterial disease; PCA, posterior cerebral artery; PV, polycythaemia vera; TIA, transient ischaemic attack; VBI, 
vertebrobasilar insufficiency. 
 
CASE NO. 
AGE/SEX/DATE 
OF DIAGNOSIS 
CV RISK FACTORS 
CEREBROVASCULAR COMPLICATIONS TREATMENT  
NEUROLOGICAL 
PRESENTATION 
CT/MRI FINDINGS AFTER PV DIAGNOSIS 
AFTER THE FIRST CEREBROVASCULAR 
EVENT 
CASE 1 
72/M/2005 
hypertension, 
hyperlipidaemia, obesity 
2011: VBI CT: mild cerebral atrophy 
medium-sized chronic ischaemic white matter 
lesions  
ASA + phlebotomy clopidogrel + phlebotomy 
CASE 2 
64/M/2010 
hypertension, 
hyperlipidaemia, 
DM 
2011: VBI 
 
CT: no pathological lesion 
MRI (2005): mild chronic ischaemic white matter 
lesions 
ASA + phlebotomy clopidogrel + hydroxyurea 
CASE 3 
70/M/2008 
hypertension, 
hyperlipidaemia, 
MTHFR C677T 
homozygous 
polymorphism (with 
currently normal 
homocystein levels) 
05/2011: left MCA ischaemic 
stroke (mild), dementia (mixed) 
11/2011: left hemispheric 
haemorrhagic stroke 
 
CT (05/2011): mild cerebral atrophy, lacunes in 
left basal ganglia, mild chronic left-sided 
ischaemic white matter lesions  
CT (11/2011): acute parenchymal haemorrhage 
(3×6 cm) in the left parieto-temporal region 
(concomitant anticoagulant therapy for AF); left 
MCA stenosis 
ASA + phlebotomy + (warfarin for AF) 
 
ASA + hydroxyurea + anticoagulant 
treatment (with low-therapeutic INR) 
 
CASE 4 
79/M/2001 
hypertension 2008: vertigo, suspected VBI 
 
CT: mild cerebral atrophy, some lacunes in basal 
ganglia, mild chronic ischaemic white matter 
lesions 
ASA + phlebotomy + hydroxyurea ASA + phlebotomy + hydroxyurea 
CASE 5 
53/M/2003 
hypertension, 
hyperlipidaemia, 
obesity 
2007: VBI 
2010: VBI 
 
CT: not available 
 
CT: mild cerebral atrophy 
ASA + phlebotomy ASA + phlebotomy + hydroxyurea + 
pentoxifylline 
CASE 6 
65/M/2011 
hypertension, DM 2013: right MCA stroke (mild) 
 
CT: acute infarction (2×2 cm) in right 
hemispheric white matter 
phlebotomy (warfarin for AF) 
 
CASE 7 
76/M/2006 
hypertension, 
obesity 
 
2012: left MCA stroke (mild) CT: medium-degree cerebral atrophy, chronic 
periventricular white matter lesions 
ASA +hydroxyurea + (acenocoumarol 
for AF) 
clopidogrel + (acenocoumarol for AF) 
CASE 8 
57/M/2008 
hypertension, 
hyperlipidaemia, DM, 
obesity 
2008: right MCA stroke (mild) 
2010: worsening of chronic 
neurological signs (dysarthria) 
CT (2008, 2010): cerebral atrophy, lacunes in 
basal ganglia, extensive chronic ischaemic white 
matter lesions  
ASA clopidogrel 
CASE 9 
52/F/1998 
hypertension, 
PAD 
2004: TIA (VBI) 
 
CT: negative 
 
ASA + hydroxyurea (acenocoumarol) hydroxyurea + clopidogrel + 
(acenocoumarol) 
CASE 10 
77/M/2012 
hypertension 2012: fatal right MCA 
haemorrhagic stroke 
CT: right-sided space-occupying haemorrhage in 
basal ganglia with intraventricular extension, 
chronic white matter lesions  
ASA  
CASE 11 
54/F/2013 
hypertension, 
hyperlipidaemia, 
obesity 
2014: vertigo – VBI CT: not available 
 
ASA clopidogrel 
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THE CONTRIBUTION OF CARDIOVASCULAR RISK FACTORS TO SUBSEQUENT THROMBOTIC 
COMPLICATIONS (Aim I.c) 
Univariate analyses revealed a significant overall association between thrombotic 
complications and high blood pressure (p=0.000), tobacco use (p=0.014), and obesity 
(p=0.078). Hyperlipidaemia (p=0.112) and DM (p=0.323) were not associated with an 
increased risk of subsequent thrombosis. The presence of one CV risk factor (p=0.016) or two 
or more CV risk factors (p=0.024) significantly increased the occurrence of thrombotic 
complications. Leukocytosis (WBC >11.1 G/L), however, did not increase significantly the 
risk of thrombotic events (p=0.119). The frequency of thrombotic events during follow-up 
differed significantly between PV subgroups with Hct values below or above 45% (p=0.089) 
(Table 11). 
 
Table 11. Mann–Whitney U test results in subgroups of polycythaemia vera patients 
sustaining or not sustaining thrombotic events during follow-up 
Comparison of PV patients who did or did not sustain thrombotic events during follow-up 
VARIABLES 
MANN–WHITNEY UNIVARIATE ANALYSIS p-
VALUE 
CV risk factors 
   Hypertension 0.000** 
   Hyperlipidaemia 0.112 
   Tobacco use 0.014** 
   Diabetes mellitus 0.323 
   Obesity 0.078* 
   Presence of 0 or 1 CV risk factor 0.016** 
   Presence of >2 CV risk factors  0.024** 
White blood cell count >11.1 G/L 0.119 
Haematocrit >45% 0.089* 
Significant differences at 10% are marked by * and those at 5% by **. 
CV, cardiovascular; PV, polycythaemia vera. 
 
To compare the thrombosis-free survival of patients in the presence or absence of the 
investigated CV risk factors, Kaplan–Meier curves and log-rank tests (Mantel–Cox) were 
used which indicated a significant difference of the thrombosis-free survival between PV 
patients without CV risk factors (N=20) and those with at least one CV risk factor (N=88) 
(p=0.017) (Figure 1). 
 
17 
 
 
 
Figure 1. Probability of thrombosis-free survival during haematological follow-up in 
subgroups of polycythaemia vera patients without cardiovascular risk factors and with at 
least one cardiovascular risk factor 
 
A significant difference was also observed between PV patients with at most one CV 
risk factor (N=49) and PV patients with two or more CV risk factors (N=59) (p=0.011) 
(Figure 2). 
 
Figure 2. Probability of thrombosis-free survival during haematological follow-up in 
subgroups of polycythaemia vera patients with at most one cardiovascular risk factor and 
with two or more cardiovascular risk factors 
 
In another complex overview, similar results were obtained for CV risk factors in female 
patients with MPDs; however, the study population for these analyses was defined as the sum 
of female patients with ET or PV [25]. 
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3.2 SYSTEMIC MASTOCYTOSIS 
3.2.1 GENERAL CONSIDERATIONS AND BACKGROUND OF THE SYSTEMIC 
MASTOCYTOSIS STUDY 
Mastocytosis represents one of the eight subcategories of MPNs in the 2008 WHO 
classification of myeloid neoplasms and acute leukaemia. It is an orphan disease characterized 
by the pathological accumulation of morphologically and immunophenotypically abnormal 
mast cells in one, two, or more organ systems. Organ systems most often involved are the 
bone marrow, skin, liver, and gastrointestinal tract [26]. The clinical presentation of 
mastocytosis is heterogeneous, ranging from skin-limited disease (cutaneous mastocytosis 
[CM]) affecting particularly children that may spontaneously regress to varying degrees of 
extracutaneous involvement (SM) generally seen in adults that may be associated with 
multiorgan dysfunction and a reduced survival [27-30]. 
The clinical course of SM varies from an asymptomatic form (indolent SM [ISM]) to a highly 
progressive type (aggressive SM [ASM]) or even mast cell leukaemia (MCL) [31]. 
The advanced features of the 2008 WHO classification are reflected not only in its novel, 
molecular-based nomenclature and clear diagnostic criteria supporting the differentiation 
between each subcategory but also in its high prognostic relevance for SM. In the ever largest 
clinical trial to validate this correlation, Lim et al. found that, compared to subjects with ASM 
or SM with an associated clonal haematological non-mast cell lineage disease 
(SM-AHNMD), ISM patients had a significantly better prognosis in terms of overall survival 
and leukaemia-free survival. Furthermore, there was no significant difference between the life 
expectancy of ISM patients and the age- and sex-matched American (USA) population for the 
appropriate time period, based on the date of diagnosis [27]. 
According to their clinicopathological features, the revised 2008 WHO classification 
distinguishes several subcategories within the group of MCDs. 
As per the 2008 WHO criteria outlined in Tables 12–13, the following categories of SM are 
defined: ISM, SM-AHNMD, ASM, and MCL. The diagnosis of SM can only be confirmed 
after the identification of morphological, immunophenotypic, and/or mutational 
characteristics of the neoplastic mast cells in an extracutaneous tissue, usually in the bone 
marrow. In addition, the WHO classification includes CM and rare, localized mast cell 
tumours, namely mast cell sarcoma (MCS) and extracutaneous mastocytoma. These entities 
do not fall under the category of SM and were therefore not included in our research aimed 
exclusively at the investigation of SM cases. 
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Table 12. WHO classification of mastocytosis [13, 30, 32] 
1. Cutaneous mastocytosis (CM) 
a. Urticaria pigmentosa/maculopapular CM (UP/MPCM) 
b. Diffuse CM (DCM) 
c. Solitary mastocytoma of the skin 
2. Indolent systemic mastocytosis (ISM): 
Meets criteria for SM. No C findings. No evidence of associated clonal haematological non-mast cell 
lineage disease. 
a. Smouldering SM (SSM): As above (ISM) but with two or more B findings and no C 
findings. 
b. Isolated bone marrow mastocytosis: As above (ISM) with bone marrow involvement but 
without skin involvement. 
3. SM with an associated clonal haematological non-mast cell lineage disease (SM-AHNMD):  
Meets criteria for SM and criteria for AHNMD as a distinct entity per WHO classification. 
4. Aggressive SM (ASM): 
Meets criteria for SM. One or more C findings. No evidence of MCL. 
5. Mast cell leukaemia (MCL): 
Meets criteria for SM. Bone marrow biopsy shows a diffuse infiltration, usually compact, by atypical 
immature mast cells. Bone marrow aspirate smears show ≥20% mast cells. In typical MCL, mast cells 
account for ≥10% of peripheral blood white cells. Rare variant: aleukaemic MCL. 
6. Mast cell sarcoma (MCS) 
7. Extracutaneous mastocytoma 
CM, cutaneous mastocytosis; ASM, aggressive systemic mastocytosis; MCL, mast cell leukaemia; MCS, mast 
cell sarcoma; UP, urticaria pigmentosa; AHNMD, associated clonal haematological non-mast cell lineage 
disease. 
 
Table 13. B and C findings in advanced mastocytosis 
B findings 
1. Bone marrow biopsy showing >30% infiltration by mast cells (focal, dense aggregates) 
and/or serum total tryptase level >200 ng/mL. 
2. Signs of dysplasia or myeloproliferation in non-mast cell lineage(s), but insufficient criteria 
for definitive diagnosis of a haematopoietic neoplasm (AHNMD), with normal or slightly 
abnormal blood counts. 
3. Organomegaly: palpable hepatomegaly, splenomegaly, or lymphadenopathy (on CT or US 
>2 cm) without impaired organ function. 
C findings 
1. Cytopenia(s) (ANC <1.0×109/L, Hb <10 g/dL, or PLT <100×109/L) but no obvious 
non-mast cell haematopoietic malignancy. 
2. Palpable hepatomegaly with impairment of liver function, ascites, and/or portal 
hypertension. 
3. Skeletal involvement with large osteolytic lesions and/or pathological fractures. 
4. Palpable splenomegaly with hypersplenism. 
5. Malabsorption with weight loss due to gastrointestinal mast cell infiltrates. 
AHNMD, associated clonal haematological non-mast cell lineage disease; ANC, absolute neutrophil count; CT: 
computed tomography; Hb, haemoglobin; PLT, platelet; US, ultrasonography. 
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The diagnosis of SM can be made when the major criterion and ≥1 minor criterion, OR 
≥3 minor criteria are present (Table 14). 
 
Table 14. Schematic overview of the 2008 WHO diagnostic criteria of systemic 
mastocytosis[30] [33] 
Major criterion 
Multifocal, dense infiltrates of mast cells (≥15 mast cells in aggregates) detected in bone 
marrow and/or other extracutaneous organs 
Minor criteria 
a. >25% of the mast cells in bone marrow or other extracutaneous organ(s) show an abnormal 
morphology in bone marrow smears or in histologies 
b. KIT mutation at codon 816 in extracutaneous organ(s) 
c. Mast cells in bone marrow express CD2 and/or CD25 
d. Serum total tryptase >20 ng/ml (does not count in patients with AHNMD-type disease) 
AHNMD, associated clonal haematological non-mast cell lineage disease. 
 
Although there is no internationally accepted, universal definition for orphan diseases, 
the different criteria are common in their use of prevalence rates. The prevalence threshold 
varies widely between the European Union, the USA, and Japan. According to the definition 
of the European Committee for Orphan Medicinal Products, severe or life-threatening 
conditions with a prevalence of less than 5:10,000 are considered as orphan diseases [34, 35]. 
Up to now, there are only very limited data on the incidence and prevalence of mastocytosis. 
Therefore, ECNM has established a registry to collect information from a number of patients 
suffering from this rare disease [36]. Within this program, an incidence of 5 to 10 cases per 
1,000,000 person-years was obtained [33]. 
The prevalence of mastocytosis in Central Europe is estimated at 0.5-1.0:10,000 [37]. 
Population-based epidemiological data and local/regional data on ISM have been reported 
from Denmark and The Netherlands (Groningen) but ECNM is still collecting data from ten 
European countries [36, 38, 39]. ISM is the most frequent subtype of SM in adults. It is 
predominated by cutaneous manifestations (UP) but recurrent systemic symptoms (e.g. 
flushing, palpitations, muscle cramps, abdominal pain, diarrhoea, bone pain) related to mast 
cell degranulation and mediator release and/or allergies or anaphylaxis may also occur. 
Factors which may lead to mast cell activation include heat, cold, stress (physical or 
emotional), medications, insect bites, and food or are idiopathic. The symptoms may have a 
strong negative impact on the quality of life while anaphylactic reactions can be severe or 
even fatal [26, 38]. 
21 
 
 
On the contrary, symptoms in ASM (e.g. cytopenia, ascites, malabsorption, or 
osteolytic skeletal lesions) arise from organ dysfunction due to mast cell infiltration. 
SM-AHNMD is characterized by the presence of another clonal haematological disease such 
as myelodysplastic syndrome (MDS), myeloid leukaemia or another MPN, or non-Hodgkin 
lymphoma concomitant to SM [26, 38]. Mast cells are tissue resident cells of HSC origin. The 
differentiation and survival of mast cells is mainly regulated by the activation of KIT by its 
ligand stem cell factor [40, 41] Most of the adult patients suffering from mastocytosis, 
regardless of disease subtype, harbour the somatic activating mutation of the oncogenic 
receptor tyrosine kinase KIT gene (exon 17, D816V) [33, 42-45] The KIT D816V mutation, 
which is found in up to 85% of all SM patients, is of great pathogenetic and diagnostic 
relevance [26, 43-45] 
3.2.2 PATIENTS AND DATA COLLECTION 
Between 2001 and 2013, a total of 35 patients were diagnosed with SM (20 males, 
15 females; median age: 57 years [range: 31–85 years]) in our centre: 14 with ISM, 15 with 
SM-AHNMD, and 6 with ASM subtypes, respectively (Table 15). In the investigated period, 
no other MCD entities like MCL, extracutaneous mastocytoma, or MCS occurred. Out of all 
registered cases, only those who strictly fulfilled the 2008 WHO criteria for SM (major 
criterion and ≥1 minor criterion, OR ≥3 minor criteria) were considered to be enrolled in our 
research. 
In Hungary, serum tryptase determination is currently not available; however, all our 
presented cases met the 2008 WHO criteria, even without known tryptase levels. The 
haematological management of each particular patient used to be based on the current 
treatment standards available at time of diagnosis and therapy initiation [32, 46-53]. 
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Table 15. Summary of the main demographic and disease-related characteristics of the 
investigated sytemic mastocytosis study population by disease subtype 
Characteristics ISM SM-AHNMD ASM 
Main demographic characteristics 
Patients (N) 14 15 6 
   Males (N) 8 7 4 
   Females (N) 6 8 2 
Median age at diagnosis (years) (range) 55 (31–81) 57 (34–72) 65 (54–85) 
Median follow-up (months) (range) 50.5 (5–240) 25 (1–104) 20.5 (2–35) 
Disease-related characteristics 
Associated haematological disease (N) – MDS (3) 
AML (3) 
MF (2) 
ET (1) 
PV (1) 
CML (1) 
iHES (1) 
MM (1) 
PTCL (1) 
B-ALL (1) 
– 
Urticaria pigmentosa (N) 8/14 – – 
Mediator-related symptoms (N)    
skin (flush, pruritus) 5/14 – 2/6 
gastrointestinal (diarrhoea) 3/14 – – 
cardiovascular (palpitation, dizziness, syncope) 2/14 – – 
neurological 1/14 – 1/6 
anaphylaxis 2/14 – – 
Coexistent allergy (N) 
(inhalation, nutritive, drug, insect venom) 
3/14 – – 
Constitutional symptoms (N) 
(generalized weakness, fatigue, sweats, chills, 
arthralgia, myalgia) 
1/14 1/15 6/6 
Organ damage/Organopathy (N)    
Hepatomegaly /  
*hepatomegaly with elevated alkaline phosphatase 
2/14 
1/14* 
3/15  
6/6* 
Splenomegaly – 2/15 3/6 
Adenopathy  1/14 1/15 3/6 
Osteopenia/osteoporosis/osteolysis 3/14 – 3/6 
AML, acute myeloid leukaemia; ASM, aggressive systemic mastocytosis; B-ALL, B-cell acute lymphoblastic 
leukaemia; CML, chronic myeloid leukaemia; ET, essential thrombocythaemia; iHES, idiopathic 
hypereosinophilic syndrome; ISM, indolent systemic mastocytosis; MDS, myelodysplastic syndrome; MF, 
myelofibrosis; MM, multiple myeloma; PTCL, peripheral T-cell lymphoma; PV, polycythaemia vera; 
SM-AHNMD, systemic mastocytosis with an associated clonal haematological non-mast cell lineage disease. 
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3.2.3 STATISTICAL ANALYSES 
Evaluation of the survival probability in systemic mastocytosis 
The survival probability in the various SM subgroups (ISM, AHNMD, ASM) was 
estimated by Kaplan–Meier analyses. Calculated patient survival rates were compared to the 
expected survival data of age- and sex-matched Hungarian population controls obtained from 
the Hungarian Central Statistical Office. Age- and sex-matched survival statistics were 
retrieved from life tables based on a population of 1,000 newborns [22]. For each year, the 
incidence rate was calculated as the number of new cases divided by the mid-year population 
size. The latter was obtained as the mean of the population sizes on 1st January of the relevant 
year and the next year. The cumulative incidence for 13 years was computed as 
, where IRi denotes the yearly incidence rates from the first to 
the thirteenth year, and ti denotes the length of each time period which is one year in this case 
for all the 13 periods. 
3.2.4 LABORATORY METHODS 
Our haematological centre – operating as an integrated part of the 2nd Department of 
Internal Medicine and Cardiology Centre – is a regional haematological diagnostic and 
treatment centre catering for a population of approx. 1,103,463 inhabitants in south-eastern 
Hungary (Figure 3). Our data were in part retrieved from the outpatient and inpatient database 
of our centre sorted by ICD code and in part obtained from bone marrow biopsy reports 
released by the Laboratory of Tumour Pathology and Molecular Diagnostics, Szeged. All 
paediatric patients with CM and adult patients presenting with skin lesions who refused bone 
marrow biopsy were not included in our study. 
 
Figure 3. Geographical location of our regional centre catering for the population of three 
south-eastern counties of Hungary (South Great Plain region). 
Source: http://www.ksh.hu/regional_atlas_counties?lang=en 
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All bone marrow test results released since 2001 were screened for SM and 
re-assessed by morphological, immunohistochemical and molecular (PCR) methods, 
according to the 2008 WHO criteria. 
We considered only those cases as SM which strictly fulfilled the relevant 2008 WHO criteria 
(major criterion and ≥1 minor criterion, OR ≥3 minor criteria). In Hungary, serum tryptase 
determination is currently not available; however, all our presented cases met the 2008 WHO 
criteria, even without known tryptase levels. C-KIT mutation analysis is routinely performed 
on every bone marrow biopsy sample evaluated at our centre. C-KIT mutations detected by 
PCR method in this patient population were confirmed by Sanger sequencing. Out of all 
detected cases, only those were incuded in our study database which strictly complied with 
the relevant 2008 WHO criteria (major criterion and ≥1 minor criterion, OR ≥3 minor 
criteria). 
 
Immunohistochemistry 
Bone marrow trephine biopsies were fixed in neutral buffered formaldehyde 
supplemented with methanol and glucose (Schaffer’s fixative), decalcified in 12.5% (w/v) 
pH 7.0 EDTA solution (Sigma-Aldrich), and embedded into paraffin. The 
immunohistochemical reactions were executed on 2-4 μm thick formaldehyde-fixed and 
paraffin-embedded (FFPE) sections waxed in xylene and graded ethanol, and pretreated by 
heat-induced antigen retrieval. The following primary antibodies were used: anti-CD117 
(Dako, Denmark A/S), anti-CD25, anti-mast cell tryptase, anti-CD68 (Leica 
Biosystems/Novocastra), and anti-phospho-STAT5 (Santa Cruz Biotechnology, USA). 
Detection was carried out with Novolink polymer kit (Leica Biosystems/Novocastra) 
according to the manufacturer’s instructions while nuclear staining was completed with 
Mayer’s haematoxylin. 
 
DNA isolation, PCR amplification, and DNA sequencing 
Molecular tests were performed on crude DNA lysates made from FFPE tissue 
sections. Briefly, ten pieces of paraffin sections of 10 µm thickness per each bone marrow 
trephine biopsy sample were placed into sterile 1.5 ml Eppendorf tubes, mounted with 100 µl 
lysis buffer (50 mM Tris-HCl, 1.5 mM MgCl2, pH 8.0) containing 10 µl proteinase K (PK) 
solution (20 mg/ml, MBI Fermentas Life Sciences), centrifuged at 13,000 rpm for 3 min, and 
incubated at 56 oC for 18 h. Afterwards, PK was inactivated at 96 oC for 15 min and 
centrifuged at 13,000 rpm for 3 min. The retrieved supernatant was used as template in 1:10–
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1:20 dilution. PCR amplification was carried out in 25 μl reaction mixture in an Eppendorf 
Mastercycler® gradient thermal cycler. PCR parameters were as follows: 100 µM dNTP (MBI 
Fermentas Life Sciences), 1.75 mM MgCl2, 25 pmol/µl of each primer, 2 µl DNA template, 
and 1.5 IU recombinant Taq polymerase (MBI Fermentas Life Sciences) per reaction. The 
following primers were used: C-KIT-outer-Fo 5’-GCCAGAAATATCCTCCTTACTCA-3’, 
C-KIT-allele-specific-Fo 5’-GTGATTTTGGTCTAGCCAGCKT-3’, C-KIT-Re 
5’-GTTGAAACTAAAAATCCTTTGCAGGAC-3’. The temperature and timing parameters 
of the cycles were as follows: denaturation at 95 oC for 30 s, annealing at 56 oC for 30 s, 
extension at 72 oC for 30 s, last extension at 72 oC for 10 min. PCR products were run on 
12.5% polyacrylamide gel using the Mini PROTEAN® Tetra Cell (Bio-Rad Laboratories) 
electrophoresis set and visualized with AgNO3 staining. This primer set generated a 
153-basepair-long outer PCR product used as reaction control and a 111-basepair-long 
mutation-specific product. PCR products of expected size were Sanger sequenced using 
Applied Biosystems® 3500 DX series genetic analyser and evaluated with the free 
Sequence Scanner software (v1.0). The sequences obtained were run against the BLAST 
database. 
In one single case [54], we screened our patient by Sanger sequencing for the most frequently 
reported KIT mutations in exons 9, 11, and 17 in a close co-operation with the 1st Department 
of Pathology and Experimental Cancer Research, Semmelweis University, Budapest [54].  
3.2.5 RESULTS 
CLINICOPATHOLOGICAL FINDINGS ALONG WITH BONE MARROW HISTOLOGICAL FEATURES, 
MOLECULAR CHARACTERISTICS, AND LABORATORY PARAMETERS AT PRESENTATION IN A LARGE 
COHORT OF SYSTEMIC MASTOCYTOSIS PATIENTS (Aim II.a) 
In the ISM group, bone marrow biopsy analysis revealed ISM in 14 patients (8 males 
and 6 females) with a median age of 55 years (range: 31–81 years). The median duration of 
follow-up was 50.5 months (range: 5–240 months). Cutaneous manifestation (UP) was 
detected in 57% (8/14) of the patients while mediator-related symptoms occurred in 28% 
(4/14) of them. 78% (11/14) of the ISM patients were positive for KIT D816V mutation.  
A total of 15 patients (7 males and 8 females; median age: 57 years [range: 34–
72 years]) were diagnosed with AHNMD. The median follow-up time in this subgroup was 
25 months (range: 1–104 months). Bone marrow biopsy was done as required by signs of the 
associated neoplasm such as bone lesions or clinically significant peripheral blood count 
abnormalities, e.g. eosinophilia or elevated or decreased WBC or PLT counts. This subtype of 
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SM was associated with MDS or acute myeloid leukaemiain three cases each, with MF in two 
cases, or with ET, PV, CML, HES, multiple myeloma, peripheral T-cell lymphoma, or B-cell 
acute lymphoblastic leukaemia in one case each. In these patients, no cutaneous lesions or 
mediator-related symptoms were observed. KIT D816V mutation positivity was detected in 
80% (12/15) of the patients. 
ASM was diagnosed in 6 patients (4 males and 2 females) with a median age of 
65 years (range: 54–85 years). The median follow-up was 20.5 months (range: 2–35 months). 
Bone marrow biopsy was performed for hepatosplenomegaly with or without 
pancytopenia/anaemia/eosinophilia and weight loss. All ASM patients presented with at least 
one C finding, as defined by the 2008 WHO criteria (marked cytopenia, osteolysis with or 
without pathological fractures, ascites and elevated liver enzymes, malabsorption with 
hypoalbuminaemia, palpable splenomegaly with hypersplenism). Cutaneous lesions were 
detected in 33% (2/6) of the patients. Mediator-related symptoms occurred in one case. 
KIT D816V mutation positivity was confirmed in 83% (5/6) of the patients.  
Clinical symptoms, immunophenotypes as well as PCR and Sanger sequencing results 
for each patient are summarized in Supplement 2 to this dissertation (Appendix III) and the 
subgroup distribution (ISM; AHNMD, ASM) and detailed characteristics of these patients 
have been recently published in Supplement 1 (Appendix III) to the Clinical and Molecular 
Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population 
Between 2001–2013 – A Single-centre Experience by Imelda Marton et al. [55]. 
 
FREQUENCY OF KIT D816V MUTATION (Aim II.b) 
KIT D816V mutation positivity was detected in 78% (11/14) of ISM patients, 80% 
(12/15) of AHNMD patients and 83% (5/6) of ASM patients, respectively. Main patient 
characteristics including bone marrow biopsy test PCR and Sanger sequencing results results 
are presented in Supplement 2 to this dissertation (Appendix III ) [55]. 
 
LIFE EXPECTANCY IN SYSTEMIC MASTOCYTOSIS (Aim II.c) 
Overall disease-specific survival of SM patients was analyzed by Kaplan–Meier 
method and is demonstrated in Figure 4. 
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Figure 4. Kaplan–Meier survival curve demonstrating cumulative survival probability of 
patients with systemic mastocytosis. The survival observed in SM patients (blue) is compared 
to the expected survival of the age- and sex-matched Hungarian population (red). 
 
Similarly, survival data for each SM subtype were also generated by Kaplan–Meier analysis 
and are presented in Figure 5.  
 
Figure 5. Survival of systemic mastocytosis patients by disease subtype. Kaplan–Meier 
survival rates of SM patients classified by disease subtype – ISM (blue), AHNMD (green), and 
ASM (yellow) – were compared to the expected survival of the age- and sex-matched 
Hungarian population (red). 
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The median survival in the ASM group was 1.73 years while the survival time of the 
AHNMD patients did not reach a median during follow-up. None of the patients died during 
the follow-up period in the ISM subpopulation. The median survival for the age- and sex-
matched control population was 23.5 years. The comparison of the survival curves using 
Mantel–Cox, Breslow and Tarone–Ware tests uniformly resulted in a p-value of 0.000 
indicating significantly different survival patterns in the evaluated SM subgroups. 
Moreover, it is important to emphasize that our research identified an uncommon case 
in the investigated patient population. In our case report [54], we demonstrated a female ISM 
patient with recurrent cutaneous symptoms and a follow-up time of 27 years. This case 
illustrates that in selected cases, imatinib mesylate could be a good choice to achieve a 
reduction of skin lesions, like in this KIT D816V-negative patient. The case is presented in 
details in Appendix IV to this dissertation as the publication of Imelda Marton et al.: 
Therapeutic challenge during the long-term follow-up of a patient with indolent systemic 
mastocytosis with extensive cutaneous involvement. 
 
CUMULATIVE INCIDENCE OF SYSTEMIC MASTOCYTOSIS (Aim II.d) 
Our regional diagnostic and treatment centre receives SM patients from the population 
of south-eastern Hungary, representing a total of 1,103,463 inhabitants [56]. These data 
allowed us to calculate the cumulative incidence of SM for 13 years in the general population, 
which proved to be 0.27/10,000 in this region. 
Four patients (Cases 2, 13, 29, and 35) were excluded from this estimation of the 
cumulative incidence: although they were diagnosed in our centre, were inhabitants of another 
administrative region of Hungary. 
3.3 HYPEREOSINOPHILIC SYNDROME 
3.3.1 GENERAL CONSIDERATIONS AND BACKGROUND OF THE 
HYPEREOSINOPHILIC SYNDROME STUDY 
Traditionally, peripheral blood eosinophilia was classified as mild (absolute eosinophil 
count [AEC] from upper limit of normal to 1,500/mm3), moderate (AEC 1,500–5,000/mm3), 
and severe (AEC >5,000/mm3). Hypereosinophilia defined as AEC >1,500/mm3 may be 
asssociated with tissue damage [57-60]. The current definitions and criteria of eosinophilic 
disorders and related syndromes are often overlapping, both with each other and within the 
area of several disciplines like pathology, haematology, immunology, and allergology. Hence, 
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the establishment of multidisciplinary definitions along with refined criteria for the various 
forms of hypereosinophilia has become essential [61]. If any secondary cause of eosinophilia 
can be excluded, the condition is classified as either clonal or idiopathic primary eosinophilia, 
depending on the presence or absence of a molecular, cytogenetic, or histological evidence for 
a myeloid malignancy [59]. 
The classification of eosinophilic diseases has been revised by the updated 2008 WHO 
scheme (Table 1). CEL-NOS is one of the eight subcategories within MPNs. Reflecting the 
growing number of recurrent, molecularly defined primary eosinophilias, a new major 
category of “myeloid and lymphoid neoplasms with eosinophilia and abnormalities of 
PDGFRA, PDGFRB, or FGFR1” has been generated [62]. Idiopathic HES represents a 
distinct entity (Table 16) . 
The rearranged PDGFRA/B and FGFR1 fusion genes encode constitutively activated tyrosine 
kinases. Out of them, PDGFRA/B-rearranged neoplasms with eosinophilia are imatinib-
sensitive. Therefore, this classification has a direct therapeutical relevance, indicating imatinib 
as the appropriate definitive treatment in these conditions. The most common cytogenetic 
alteration in myeloid and lymphoid neoplasms accompanied by eosinophilia and 
abnormalities of PDGFRA is FIP1L1–PDGFRA gene fusion first described by Cools et al. in 
2003 [63]. 
 
Table 16. Schematic overview of 2008 WHO classification of eosinophilic disorders [64] 
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, 
or FGFR1 
Diagnostic criteria of an MPN with eosinophilia associated with FIP1L1–PDGFRA 
Diagnostic criteria of MPN associated with ETV6–PDGFRB fusion gene or other rearrangement 
of PDGFRB 
Diagnostic criteria of MPN or acute leukaemia associated with FGFR1 rearrangement 
Chronic eosinophilic leukaemia, not otherwise speciﬁed (CEL-NOS) 
Idiopathic hypereosinophilic syndrome (iHES) 
Exclusion of the following: 
1. Reactive eosinophilia 
2. Lymphocyte-variant hypereosinophilia (cytokine-producing, immunophenotypically aberrant 
T-cell population) 
3. Chronic eosinophilic leukaemia, NOS 
4. WHO-deﬁned myeloid malignancies-associated eosinophilia (e.g. MDS, MPNs, MDS/MPNs, 
or AML) 
5. Eosinophilia-associated MPNs or AML/ALL with rearrangements of PDGFRA, PDGFRB, or 
FGR1 
6. The absolute eosinophil count (AEC) >1,500/mm3 must persist for at least 6 months and 
tissue damage must be present. If there is no tissue damage, iHES is the preferred diagnosis. 
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Laboratory evaluation of primary hypereosinophilia should start with screening of 
peripheral blood or bone marrow for FIP1L1–PDGFRA gene fusion either by real-time PCR 
(RT-PCR) or interphase/metaphase fluorescence in situ hybridization (FISH). Abnormalities 
of PDGFRB or FGFR1 could be identified by conventional cytogenetic analysis or FISH [62]. 
Studies conducted in developed countries indicate that FIP1L1–PDGFRA fusion occurs in 
approximately 10% of patients with hypereosinophilia of unknown aetiology [65-67]. While 
imatinib mesylate (imatinib) administered in lower doses than in CML and as first-line 
treatment for patients with abnormalities of PDGFRA/B is highly effective to reach and 
maintain molecular remission, patients with FGFR1 fusions are resistant to this drug and have 
a poor prognosis [62]. 
The WHO definition of HES is based on the historical criteria outlined by Chusid 
et al. in 1975. According to these, the diagnosis of HES can be established if 
AEC >1,500/mm3 persists for >6 months and tissue damage is present without secondary 
causes of eosinophilia (such as parasitic infection, drugs, connective tissue disorders, 
vasculitis, malignancies, or allergies) [68]. However, the criterion of a 6-month-long duration 
of elevated AEC may be abandoned as the primary goal is the rapid correction of 
hypereosinophilia and the prevention of organ failure by an early and effective treatment. In 
the absence of organ damage, the preferred term is “idiopathic hypereosinophilia” instead of 
HES [69]. The proper classification is fairly difficult as, on the one hand, there is a 
considerable overlapping between the various conditions with hypereosinophilia and, on the 
other hand, the nomenclature itself has been continuously debated for decades. 
The most common signs and symptoms in HES are asthenia and fatigue (26%), cough 
(24%), dyspnoea (16%), myalgia or angiooedema (14%), rash or fever (12%), and rhinitis 
(10%) [61]. Typical laboratory findings include leukocytosis (≥20,000-30,000/mm3) with 
peripheral eosinophilia up to a level of 30-70% [70]. The clinical manifestation of HES is 
diverse ranging from an asymptomatic form to a progressive course with severe symptoms 
and multi-organ involvement. Sustained eosinophilia may affect all tissues and organ systems. 
Most frequently reported complications include dermatological, neurological, pulmonary, 
cardiac, and – less commonly – gastrointestinal conditions [70-73]. 
The major cause of morbidity and mortality is eosinophilic myocarditis developing secondary 
to endomyocardial fibrosis and restrictive cardiomyopathy. Loeffler’s endocarditis with 
eosinophilic infiltration represents the prototype of cardiac manifestations in HES [7]. The 
clinical course of Loeffler’s endocarditis typically progresses in three – necrotic, thrombotic, 
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and fibrotic – stages into endomyocardial fibrosis and restrictive endomyocardyopathy as end-
stage [74]. Many hypotheses have been proposed to explain the pathomechanism of cardiac 
and other organ dysfunctions in HES. The primary target of the tissue damage initiating local 
thrombosis is endothelial cells of the endocardium [48]. Major basic protein released from 
eosinophilic granules may exert endothelial cell damage while eosinophilic cationic protein 
may be responsible for the hypercoagulable state. The direct toxic and procoagulant effect of 
eosinophilic derivatives may contribute to the development of thrombosis and cardiac 
embolism [58-61, 71]This may explain central nervous system (CNS) injury: not only 
eosinophil-induced endothelial dysfunction but also cardiac microembolization might play an 
important role in the development of cerebral infarction and neurological dysfunction. Toxic 
effects of released eosinophilic basic proteins may initiate endomyocardial necrosis which 
occurs in the early stages and usually remains subclinical. After 4-6 weeks of disease onset 
the excessive release of tissue factor from damaged tissue cells and eosinophils may lead to 
endomyocardial fibrosis [59, 75-77]. Case series published after the first description of the 
disease reported very poor prognosis and short survival in HES, primarily due to the advanced 
state of the disease and the congestive heart failure. In a report by Chusid et al., median 
survival was as short as 9 months while 3-year survival was only 12% [68]. A later 
publication on 40 HES patients talked about a 5-year survival rate of 80%, decreasing to 42% 
at 15 years [73]. 
3.3.2 PATIENTS AND DATA COLLECTION IN THE HYPEREOSINOPHILIC SYNDROME 
POPULATION 
The diagnosis of idiopathic HES can only be established after the exclusion of all 
primary and secondary causes of hypereosinophilia and lymphocyte-variant hypereosinophilia 
[69]. We evaluated 10 iHES patients with hypereosinophilia fulfilling the 2008 WHO criteria 
but without any secondary causes or underlying clonal disease. All patients were 
asymptomatic; none of them had a known Loeffler’s endocarditis. Cytogenetic, FISH, and 
molecular analyses of FIP1L1–PDGFRA were negative for all subjects in this population of 
10 iHES patients without any underlying disease. Due to the presence of Loeffler’s 
endocarditis and the rare neurological complication, the case of the patient with FIP1L1–
PDGFRA mutation will be discussed separately. 
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Table 17. Summary of the main demographic and disease-related characteristics of the 
investigated study population with hypereosinophilic syndrome 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 STATISTICAL ANALYSES 
All HES patients and their age- and sex-matched healthy controls underwent complete 
two-dimensional (2D) Doppler echocardiography and 3DSTE. Data of altogether 10 HES 
patients were compared to matching data of 19 control subjects. 
Continuous variables were calculated as mean ± standard deviation. All statistical tests were 
two-sided. The cut-off value for statistical significance was set at p=0.05. Continuous 
parameters were compared using unpaired Student’s t test while categorical variables were 
analyzed by chi-square or Fischer’s exact test. The correlation was defined by Pearson's 
correlation coefficient. Statistical evaluations were performed using MedCalc software 
(MedCalc Inc., Mariakerke, Belgium). 
3.3.4 METHODS – LABORATORY TESTS AND ECHOCARDIOGRAPHY 
Diagnostic bone marrow samples of all patients investigated for hypereosinophilia 
were evaluated at our local tumour pathology laboratory. Cytogenetic tests were completed at 
the laboratory for cytogenetics of the 2nd Department of Internal Medicine and Cardiology 
Centre while FISH assays were performed at the Department of Haematology and Stem Cell 
Transplantation, United Szent István and Szent László Hospital, Budapest. Molecular genetic 
tests for FIP1L1–PDGFRA were carried out in a close co-operation with the team of the 
Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, 
Budapest [63]. 
Characteristics HES 
Main demographic characteristics 
Patients (N) 10 
   Males (N) 7 
   Females (N) 3 
Median age at diagnosis (years) (range) 58.1 ± 13.1 
Median follow-up (months) (range) 37 (2–120) 
Disease-related characteristics 
Red blood cell count (T/L) 4.2 ± 0.5 
Haemoglobin (g/L) 126.7 ± 18.8 
Haematocrit (%) 36.9 ± 5.5 
Platelet count (G/L) 276.3 ± 176.7 
White blood cell count (G/L) 16.7 ± 5.8  
Percentage of blood eosinophils (%) 49.0 ± 16.6 
Absolute eosinophil count (G/L) 8.7 ± 4.8 
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Three-dimensional speckle-tracking echocardiography (3DSTE) 
3DSTE datasets were acquired from apical window using the 1–4 MHz matrix phased-
array transducer (PST-25SX) [78]. 
Following gain setting optimization, full volume mode was used over six consecutive cardiac 
cycles during a single breath-hold. Volume data were stored in raw data format for further 
analysis. LA quantifications were performed using the Artida 3D Wall Motion Tracking 
software v2.7 (Toshiba Medical Systems, Tokyo, Japan). Each three-dimensional (3D) dataset 
was displayed in multiple plane views including the apical two- (AP2CH) and four-chamber 
(AP4CH) views and three short-axis views at different LA levels from the base to the apex. 
Several reference points on the LA endocardium were set by the examiner in the AP2CH and 
AP4CH views. The first points were set at the edge of the septal mitral valve ring where 
anterior mitral leaflet origins and then markers were placed in a counterclockwise rotation 
around the LA to the lateral mitral valve ring (to the origin of the posterior leaflet) in the 
AP4CH viewing plane. During evaluations, LA appendage and the pulmonary veins were 
excluded from the LA cavity. Measurements were performed first on AP4CH view and then 
on AP2CH view. After detection of the LA myocardial borders at the end-diastolic reference 
frame, the user could correct the LA shape if it was necessary. The 3D wall motion tracking 
was then automatically performed through the entire cardiac cycle. 
 
3DSTE for left atrial volumetric measurements 
From time curves of global LA volume changes, maximum (Vmax), minimum LA 
volumes (Vmin) and LA volume before atrial contraction (VpreA) were measured using the 3D 
echocardiographic datasets just before mitral valve opening (end-systole), just before mitral 
valve closure (end-diastole) and at time of P-wave on electrocardiography (early diastole), 
respectively [78-82] LA function consists of three phases: the systolic reservoir phase and the 
diastolic passive (conduit) and active emptying (booster pump) phases. To characterize these 
functions, stroke volumes (SVs) and emptying fractions (EFs) were calculated from the 
above-mentioned volumes as follows: 
   Left atrial stroke volumes 
- Total Atrial Stroke Volume (TASV): Vmax−Vmin (reservoir function) 
- Passive Atrial Stroke Volume (PASV): Vmax–VpreA (conduit function) 
- Active Atrial Stroke Volume (AASV): Vpre A−Vmin (booster pump/active contraction 
function) 
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   Left atrial emptying fractions 
- Total Atrial Emptying Fraction (TAEF): TASV/Vmax×100 (reservoir function) 
- Passive Atrial Emptying Fraction (PAEF): PASV/Vmax×100 (conduit function) 
- Active Atrial Emptying Fraction (AAEF): AASV/VpreA×100 (booster pump/active 
contraction function) 
 
3DSTE for left atrial strain measurements 
From the same 3D echocardiographic datasets, time curves of unidirectional radial 
(RS), longitudinal (LS), and circumferential strain (CS) were also generated for each segment 
using the 16-segment model obtained for LV [81-84] Moreover, due to the ability of 3DSTE 
to calculate complex strains, area strain (the ratio of endocardial area change during cardiac 
cycle) and 3D strain (strain in the direction of wall thickening; combination of 
“unidirectional” strains) were also measured. At each time, segmental strain curve peak 
strains representing characteristics of reservoir phase of the LA function were measured. 
Global strains were calculated by the software considering the whole LA while mean 
segmental strains were obtained as the average of strains of 16 segments as well. These 
parameters were calculated automatically by the software. 
3.3.5 RESULTS 
COMPARISON OF LEFT ATRIAL VOLUMETRIC, VOLUME-BASED FUNCTIONAL, AND STRAIN PARAMETERS 
OBTAINED BY THREE-DIMENSIONAL SPECKLE-TRACKING ECHOCARDIOGRAPHY, A NOVEL, 
NON-INVASIVE CLINICAL TOOL FOR VOLUMETRIC AND STRAIN ANALYSIS, BETWEEN PATIENTS WITH 
HYPEREOSINOPHILIC SYNDROME AND MATCHED CONTROLS (Aim III.a) 
On routine haematological testing, the following results (HES vs. controls) were 
obtained: RBC: 4.2 ± 0.5 T/L vs. 4.3 ± 0.4 T/L (p=0.94), haemoglobin: 126.7 ± 18.8 g/L vs. 
130.1 ± 10.2 g/L (p=0.86), PLT: 276.3 ± 176.7 G/L vs. 282.4 ± 158.2 G/L, Htc: 36.9 ± 5.5% 
vs. 37.8 ± 4.9%, WBC: 16.7 ± 5.8 G/L vs. 6.8 ± 1.2 G/L (p=0.02), eosinophil ratio: 
49.0 ± 16.6% vs. 3.2 ± 2.3% (p=0.001), and AEC: 8.7 ± 4.8 G/L vs. 0.4 ± 0.1 G/L (p=0.001). 
No correlation was found between any of the laboratory findings and 2D echocardiographic or 
3DSTE data in this patient population. None of the control and HES patients exhibited 
>Grade 1 mitral or tricuspid regurgitation. Significant difference was only found in LA 
diameter and interventricular septum thickness between HES and control subjects. Clinical 
data of each patient with organic involvement are presented in Table 18. Only one patient had 
a prior cardiac disease (NSTEMI) in his history. 
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Table 18. Clinical data of patients with hypereosinophilic syndrome 
CASE NO. 
AGE/SEX/DATE 
OF DIAGNOSIS 
ORGANIC INVOLVEMENT HEPATOMEGALY, 
SPLENOMEGALY 
CARDIAC DISEASE 
(YEAR) 
Case 1 
52/M/2013 
duodenal eosinophilia splenomegaly – 
Case 2 
71/M/2009 
– – – 
Case 3 
44/M/2010 
– – – 
Case 4 
66/F/2011 
tissue eosinophilia – – 
Case 5 
77/M/2013 
– – NSTEMI (2013) 
Case 6 
69/F/2009 
eosinophil dermatitis – – 
Case 7 
45/M/2011 
sensoral motoneuritis, pulmonal 
affection, sural necrotising 
granulomatous vasculitis 
splenomegaly – 
Case 8 
59/M/2013 
– – – 
Case 9 
41/F/2002 
– – – 
Case 10 
73/F/2014 
bronchial asthma, vasculitis – – 
NSTEMI, non–ST-segment elevation myocardial infarction 
 
As reflected by 3DSTE data, both global and mean segmental peak CS were significantly 
reduced in HES patients suggesting an impaired LA reservoir function (Table 19). 
 
Table 19. Comparison of 3DSTE-derived global and mean peak segmental strain parameters 
of patients with hypereosinophilic syndrome and controls 
 
HES patients 
(N=10) 
Controls 
(N=19) 
p-value 
Global strain parameters    
   Radial strain (%) -17.7 ± 7.7 -15.7 ± 11.6 0.64 
   Circumferential strain (%) 18.3 ± 6.7 25.6 ± 9.0 0.03 
   Longitudinal strain (%) 21.0 ± 6.2 22.3 ± 8.7 0.68 
   3D strain (%) -10.1 ± 5.0 -9.3 ± 9.0 0.81 
   Area strain (%) 41.2 ± 13.8 50.7 ± 20.4 0.20 
Mean segmental strain parameters    
   Radial strain (%) -20.6 ± 6.1 -19.5 ± 8.1 0.70 
   Circumferential strain (%) 22.2 ± 6.0 31.0 ± 12.1 0.04 
   Longitudinal strain (%) 21.8 ± 6.4 25.6 ± 7.5 0.18 
   3D strain (%) -14.7 ± 4.3 -13.7 ± 6.7 0.67 
   Area strain (%) 45.6 ± 13.1 58.3 ± 21.7 0.10 
3D, three-dimensional; HES, hypereosinophilic syndrome. 
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Significantly increased maximum (p=0.01) and minimum (p=0.03) LA volumes as well as LA 
volume before atrial contraction (p=0.01) and elevated total (p=0.02) and active (p=0.005) 
atrial SVs values characterizing reservoir and booster pump LA function were found in HES 
patients, as compared to controls. EF did not significantly differ between groups (Table 20). 
 
Table 20. Comparison of 3DSTE-derived volumetric and volume-based functional left atrial 
parameters of patients with hypereosinophilic syndrome and controls 
 
HES patients 
(N=10) 
Controls 
(N=19) 
p-value 
Calculated volumes    
   Maximum LA volume (Vmax, mL) 72.9 ± 38.8 45.6 ± 15.5 0.01 
   Vmax / BSA (mL/m2) 41.8 ± 25.0 26.0 ± 9.7 0.03 
   Vmax / BMI [mL/(kg/m2)] 2.8 ± 1.5 1.8 ± 0.6 0.03 
   Minimum LA volume (Vmin, mL) 46.3 ± 33.3 26.0 ± 15.0 0.03 
   Vmin / BSA (mL/m2) 26.8 ± 21.4 14.9 ± 9.7 0.05 
   Vmin / BMI [mL/(kg/m2)] 1.7 ± 1.2 1.0 ± 0.6 0.05 
   LA volume before atrial contraction (VpreA, 
mL) 
62.0 ± 36.0 36.5 ± 16.6 0.01 
   VpreA / BSA (mL/m2) 35.7 ± 23.1 20.9 ± 10.4 0.03 
   VpreA / BMI [mL/(kg/m2)] 2.3 ± 1.4 1.4 ± 0.7 0.03 
Stroke volumes (SVs)    
   Total atrial SV (TASV, mL) 26.6 ± 8.5 19.6 ± 6.4 0.02 
   TASV / BSA (mL/m2) 15.0 ± 4.9 11.1 ± 3.6 0.04 
   TASV / BMI [mL/(kg/m2)] 1.0 ± 0.3 0.8 ± 0.3 0.12 
   Passive atrial SV (PASV, mL) 10.9 ± 8.2 9.1 ± 5.0 0.47 
   PASV / BSA (mL/m2) 6.1 ± 4.6 5.1 ± 2.8  0.61 
   PASV / BMI [mL/(kg/m2)] 0.4 ± 0.3 0.4 ± 0.2 0.78 
   Active atrial SV (AASV, mL) 15.7 ± 5.1 10.5 ± 4.0 0.005 
   AASV / BSA (mL/m2) 8.9 ± 2.9 5.9 ± 2.3 0.01 
   AASV / BMI [kg/(mL/m2)] 0.6 ± 0.2 0.4 ± 0.2 0.03 
Emptying fractions (EFs) (%)    
   Total atrial EF 40.0 ± 10.5 45.0 ± 12.9 0.29 
   Passive atrial EF 15.9 ± 11.7 21.4 ± 10.8 0.21 
   Active atrial EF 28.6 ± 7.8 30.5 ± 9.5 0.58 
BMI, body mass index; BSA, body surface area; HES, hypereosinophilic syndrome; LA, left atrial. 
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PRESENTATION OF LEFT VENTRICULAR ROTATIONAL MECHANICS THROUGH A UNIQUE CASE OF 
HYPEREOSINOPHILIC SYNDROME WITH LOEFFLER'S ENDOCARDITIS BY MEANS OF THE NOVEL 
METHOD OF 3DSTE (Aim III.b) [85] 
Loeffler’s disease is associated with stiffened ventricular and atrial walls leading to 
inadequate filling, decreased preload, diastolic dysfunction, and heart failure. At this moment, 
little is known about the rotational characteristics of the Loeffler’s heart. Therefore, we 
present a 36-year-old male patient with known Loeffler’s endocarditis on optimal therapy 
whose rotational parameters were evaluated by 3DSTE. The multiple long- (A, B) and short-
axis views (C3, C5, C7) extracted from a 3D echocardiographic dataset are shown in Figure 6. 
Visual information on LV rotation is given in colour overlay superimposed on grey-scale 
images. Moreover, a 3D cast of LV (Figure 6D) and calculated LV volumes, ejection fraction 
(EF), and estimated LV mass are also demonstrated (Figure 6E). Quantitative data are 
provided on LV rotation with adequate rotational directions with counterclockwise motion of 
the LV apex (white arrow, positive value) and clockwise motion of the LV base (dashed 
arrow, negative value) (Figure 6F). Both LV apical and basal rotation were in normal range 
suggesting normal rotational characteristics despite reduced systolic function in this case with 
known Loeffler’s disease. Data of a control subject are also presented in the same fashion 
(Figure 7) [85]. 
 
Figure 6. Apical four-chamber (A) and two-
chamber (B) views and short-axis views (C3, C5, 
C7) at different levels of the left ventricle (LV) 
extracted from the three-dimensional (3D) 
echocardiographic dataset. A 3D cast of the LV (D) 
and calculated volumetric and functional LV 
parameters (EDV, end-diastolic volume; ESV, end-
systolic volume; EF, ejection fraction; est LV MASS, 
estimated left ventricular mass) are also 
demonstrated (E). Counterclockwise rotation of LV 
apex (white arrow, positive value) and clockwise 
rotation of LV base (dashed arrow, negative value) are also shown demonstrating normal rotational 
directions in this Loeffler patient’s heart (F). 
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Figure 7. Apical four-chamber (A) and two-
chamber (B) views and short-axis views (C3, C5, C7) 
at different levels of the left ventricle (LV) extracted 
from the three-dimensional (3D) echocardiographic 
dataset. A 3D cast of the LV (D) and calculated 
volumetric and functional LV parameters (EDV, end-
diastolic volume; ESV, end-systolic volume; EF, 
ejection fraction; est LV MASS, estimated left 
ventricular mass) are also demonstrated (E). 
Counterclockwise rotation of LV apex (white arrow, 
positive value) and clockwise rotation of LV base 
(dashed arrow, negative value) are also shown demonstrating normal rotational directions in a 
healthy subject (F). 
Moreover, it is important to emphasize that our research identified an uncommon case 
in the investigated patient population. Due to its unique nature and potential clinical 
relevance, we demonstrated it in a separate case report, providing therefore an additional 
proof of the complexity of HES [86]. The case is presented in details in Appendix VI to this 
dissertation as the publication of Imelda Marton et al.: Watershed infarction in 
hypereosinophilic syndrome: a diagnostic dilemma in FIP1L1–PDGFR-alpha-associated 
myeloid neoplasm and overview of the relevant literature [86]. 
4 DISCUSSION 
4.1 POLYCYTHAEMIA VERA 
PV, the most common BCR–ABL1-negative classic MPN is a HSC-derived clonal 
myeloproliferation characterized by a trilineage expansion of morphologically normal red 
cells, white cells, and platelets without significant bone marrow fibrosis. At the 
2nd Department of Internal Medicine and Cardiology Centre, which is a regional 
haematological centre for the population of south-eastern Hungary, data on 108 PV patients 
were available from the period between 1998 and 2014. As reported [10], the incidence of PV 
varies from 0.4 to 2.8 cases per 100,000 persons per year in the European Union; the median 
age at diagnosis is around 61 years (range: 18–95 years) [11]. The occurrence of PV is a bit 
higher in men than in women (2.8 vs. 1.3 cases per 100,000 persons per year [12]. In our 
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study, demographics like distribution by gender and mean age at diagnosis were highly 
consistent with corresponding data in the literature. 
The diagnostic criteria of PV have been changed several times since the first edition of the 
PVSG criteria in 1975. The identification of JAK mutation fundamentally affected the 
diagnosis of PV. The acquired JAK2 V617F somatic mutation causes cytokine-independent 
activation of several biochemical pathways involved in the erythropoietin receptor signalling. 
Given that more than 90% of PV patients carry this particular mutation, it has been 
incorporated into the 2008 WHO diagnostic criteria. The lack of clear diagnostic criteria in 
the past often resulted a proportion of secondary polyglobulia cases to be diagnosed and 
followed as PV. Therefore, we strictly adhered to the 2008 WHO criteria while establishing 
our PV database and excluded all polyglobulia cases which did not meet these criteria (i.e., 
cases without JAK2 mutation, combined with normal or increased serum erythropoietin 
levels). The proportion of PV patients with JAK2 V617F mutation in our PV database was 
94.4% which correlates well with the existing literature [17]. The incidence of JAK2 exon 12 
mutation (which has a reported frequency of 3%) was not investigated in our research.While 
earlier studies estimated the rate of vascular events to 12–39% and reported about various 
manifestation forms [18], recent works have also confirmed their incidence well above 20% 
[17]. Arterial events occur typically much more frequent than venous ones [20]. 
In PV, thrombosis (splanchnic venous thrombosis or cerebral sinus thrombosis) is 
often an initial occurrence which may suggest the diagnosis as early as before the 
haematological verification. In our study, the prediagnostic incidence of major thrombotic 
events was 33/108 (30,5%), highly similar to literature data [87]. Another research found the 
frequency of pre- and peridiagnostic major vascular events as 16% for arterial and 7% for 
venous complications, respectively, while the incidence of haemorrhagic events made up 4% 
[88]. In the largest prospective European PV study (European Collaboration Study on Low-
dose Aspirin in Polycythemia – ECLAP, 2004), the same incidence rates accounted for 27%, 
11%, and 9.2%, respectively [89]. Later investigations like the CYTO-PV trial (2013) 
reported 17% and 12% for the incidence of arterial and venous complications, respectively, 
while these numbers were 12% and 9% in another study conducted in 1545 patients by Tefferi 
et al. (2013) [11, 88, 90]. Decreasing incidence rates might be explained by the evolution of 
diagnostic criteria and the incorporation of novel knowledge into the therapeutic regimens 
(e.g., based on results from the ECLAP study, wider use of ASA, more aggressive 
phlebotomy policy for more restrictive Hct target, introduction of cytoreductive treatment, 
and more intensive management of CV risk factors). 
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In our PV patient cohort representing the period from 1998 to 2014, a total of 20 major 
vascular complications were observed in 108 patients (18.5%); among them, arterial events 
(n=18; 16.6%) occurred more frequently then venous ones (n=2; 1.8%). The frequency of 
total vascular and arterial events in our research was similar to those in the above trials, with 
consistently lower rates for venous thrombotic events. Furthermore, we thoroughly 
investigated the incidence of CV events during follow-up and found them to occur in 7 cases 
in 108 patients (6%). This means, six out of seven PV patients were available for an adequate 
cardiological analysis of CV complications during follow-up. All patients belonged to the 
high-risk group and five of them (83%) had at least two or more conventional CV risk factors. 
The frequency of AMI in our PV cohort was higher (6%) than that reported in trials on larger 
patient populations (2%) [88]. 
Compared to the literature (7%), we detected a markedly higher frequency for 
cerebrovascular events (11/108; 10.1%) [88]. The occurrence of cerebrovascular 
complications in our PV cohort also exceeded the incidence of stroke reported earlier in the 
general Hungarian population (2/1,000 in the age of 45–54 years, 3/1,000 in the age of 55–
64 years, and 3–13/1,000 above the age of 65 years; 2005) [91]. In most cases, chronic 
ischaemic white matter lesions were observed. Mild cerebral atrophy was also a frequent 
finding. The clinical presentation of cerebrovascular events was predominated by lacunar 
syndromes or VBI. Most of these patients (8/11; 72%) also presented at least two major 
conventional CV risk factors. The slightly higher AMI and stroke incidence rates in our PV 
cohort might be attributed to our less stringent – yet historically guideline-compliant – attitude 
in terms of Hct targets and the introduction of cytoreductive treatment at that time; i.e., our 
treatment strategy used to be based on the conventional two-level risk assessment. In addition, 
the significant additional effect of CV risk factors on thrombotic events was only partially 
acknowledged and this approach in PV management was therefore much less dominant. 
Although CV risk factors were incorporated into the IPSET score in 2012 for purposes 
of thrombosis risk stratification in ET, the same practice is still disputed for PV [92]. The 
results of our research in PV in terms of the incidence of CV and cerebrovascular 
complications and the contribution of CV risk factors to subsequent thrombotic complications 
clearly demonstrate the importance of considering PV as a prothrombotic state where 
conventional CV risk factors (hypertension, tobacco use, hyperlipidaemia, obesity, DM) may 
significantly increase the risk of thrombotic events. The complete pathomechanism of 
prothrombotic processes in PV remains, however, to be understood. Falanga et al. carried out 
intensive investigations on the correlation between MPNs and thromboses and found the 
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pathogenesis to be particularly complex and multifactorial. The higher thrombosis risk in PV 
can be considered as a result of as a consequence of an acquired thrombophilic state 
associated with the underlying disease. This might be partly explained by the prothrombotic 
characteristics of MPN clone-derived blood cells and the procoagulant response of normal 
epithel cells to inflammatory stimuli. In addition, higher Hct rates result in blood 
hyperviscosity. The greater red cell mass displaces platelets toward the vessel wall, thus 
facilitating shear-induced platelet activation and aggregation and enhancing platelet-platelet 
interaction. Moreover, changes of the red cell membrane trigger the formation of erythrocyte 
aggregates. Finally, all these processes together are responsible for the increased coagulability 
of blood in PV [20]. Although the recommended Hct level was questioned for a long time, 
[93], current gudelines clearly indicate a target of 45% in PV [17, 21, 90]. Our observation 
that the frequency of thrombotic events during follow-up differed significantly between PV 
subgroups with Hct values below or above 45% is well reflected by the latest therapeutic 
recommendations. 
Currently, no data are available whether the presence of one CV risk factor or two or 
more CV risk factors considerably increases the occurrence of thrombotic complications in 
PV. Our research demonstrated that there is a significant difference in the thrombosis-free 
survival between PV patients with or without at least one CV risk factor. The difference is 
also significant for the comparison of PV patients with at most one CV risk factor or at least 
two CV risk factors. These results were further confirmed by our study to evaluate the role of 
CV risk factors in major thrombotic complications in the pooled population of female patients 
with ET or PV. In this setting, the presence of two or more CV risk factors was associated 
with a significantly higher risk of thrombosis. Moreover, a significant difference was seen in 
the thrombosis-free survival between patients with at most one CV risk factor and those with 
two or more CV risk factors [25]. Female patients with CV risk factors and PV or ET may 
well be at a higher risk of thrombotic events, and require therefore a special consideration for 
the prevention and management of thrombotic events. 
Regarding thrombotic events, the evaluation of additional risk factors is a novel 
approach. The first papers emphasizing the role of CV risk factors in addition to conventional 
risk assessment (age >60 years and/or prior thrombotic event) were published in the last year 
of our research. Moreover, the 2015 update on PV management by Tefferi et al. implementing 
new results provides much more complex recommendations than the previous versions used 
to be based on a two-level (low or high) risk assessment [17]. Although CV risk factors were 
not incorporated in the risk stratification of the 2015 guidelines of the European Society for 
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Medical Oncology, they are taken into account in their risk-adapted therapy recommendations 
[94]. Given that in PV, thrombohaemorrhagic events represent the leading cause of morbidity 
and mortality, the therapy primarily aims to prevent these complications without increasing 
the bleeding risk, and only secondarily to control the symptoms. Therefore, treatment should 
always be individually adjusted to thrombosis and/or bleeding risk. Knowledge is being 
continuously updated and implemented in the guidelines, resulting in even more stringent 
therapeutic recommendations. Controlled trials showed the reduction of thrombosis risk with 
low-dose ASA and cytoreductive therapy in high-risk patients, without affecting the survival 
[89, 90]. Our results support the importance of individualized treatment – considering each 
patient’s thrombosis and/or bleeding risk – and more aggressive management of modifiable 
risk factors (e.g. CV risk factors) with restrictive targets in PV. 
Patients defined as being at low risk according to previous therapeutic guidelines (age 
<60 years, without prior thrombotic event) used to be treated with anti-platelet agents (e.g. 
ASA) and by phlebotomy, while high-risk patients (age ≥60 years and/or with prior 
thrombotic event) used to receive cytoreductive drugs (e.g. hydroxyurea) combined with 
anti-platelet therapy. Current therapeutic recommendations for PV are largely adapted to 
individual risk profile. For low-risk patients (age <60 years and negative thrombosis history 
and the presence of JAK2 V617F mutation or CV risk factor(s)) without extreme 
thrombocytosis, low-dose ASA once daily is recommended; in case of CV risk factors with 
concomitant JAK2 V617F mutation positivity ASA twice daily should be considered. In low-
risk patients with extreme thrombocytosis (PLT >1,000×109/L), the measurement of ristocetin 
cofactor activity is necessary (administration of ASA if >30%). High-risk patients (age 
≥60 years and/or positive thrombotic history) without prior thrombotic events should be 
treated with hydroxyurea + once daily low-dose ASA. In case of previous arterial thrombotic 
event, hydroxyurea + ASA should be given, with the consideration of ASA twice daily if any 
or more of the following are present (CV risk factor(s), JAK2 V617F mutation positivity, age 
>60 years). For high-risk patients with previous venous event, hydroxyurea with life-long 
anticoagulation is recommended, given the concept of PV as an acquired persistent 
thrombophilic state. The addition of ASA once daily should also be considered if any or more 
of the following are present (CV risk factor(s), JAK2 V617F mutation positivity, age 
>60 years). In all patients, pharmacological therapy should always be completed by 
phlebotomy to target Hct <45% [17, 95]. For high-risk patients refractory to or intolerant of 
hydroxyurea, interferon-alpha (IFN-alpha; age <65 years) or busulphan (age >65 years) may 
be an option. The selective JAK1/2 inhibitor ruxolitinib approved in 2015 for the treatment of 
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adult patients with PV who are resistant to or intolerant of hydroxyurea is not yet widely 
available in Hungary. 
4.2 SYSTEMIC MASTOCYTOSIS 
Mastocytosis is an orphan disease characterized by the clonal neoplastic proliferation 
of mast cells accumulating in one or more organ systems. Out of the several manifestations of 
adult mastocytoses, our research targeted adult SM. According to the 2008 WHO criteria, SM 
is classified as ISM, SM-AHNMD, ASM, and MCL. In our regional centre, 14 ISM, 
15 AHNMD, and 6 ASM cases were diagnosed in the period between 2001 and 2013; MCL 
was, however, not detected in any patient. As our study aimed at the evaluation of histological 
features, molecular characteristics as well as laboratory and clinical parameters of adult SM, 
mastocytosis cases in paediatric patients or those in adults confined only to the skin (without 
available bone marrow biopsy results) were not included in our research. All bone marrow 
test results since 2001 were screened for SM and re-assessed by morphological, 
immunohistochemical, and molecular (PCR) methods, according to the 2008 WHO criteria. 
ISM is the most frequent subtype of SM in adults. It is predominated by cutaneous 
manifestations (UP) but recurrent systemic symptoms related to mast cell degranulation and 
mediator release and/or allergies or anaphylaxis may also occur. A wide range of factors may 
lead to mast cell activation, resulting in severe or even life-threatening or fatal symptoms [26, 
38]. In our SM study population, cutaneous manifestation (UP) was detected in 57% (8/14) of 
the patients while mediator-related symptoms occurred in 28% (4/14) of them. 
In our study, the main cause of the indication of bone marrow biopsy in the group of ISM 
patients was UP (8/14; 57%). It is important therefore that dermatologists should refer any 
patient with CM lesions to a haematological centre to check potential bone marrow 
involvement. In other cases, bone marrow biopsy was performed for eosinophilia (3/14; 21%), 
anaemia (1/14; 7%), lytic bone lesions (1/14; 7%), or adenomegaly (1/14; 7%). 
On the contrary, symptoms in ASM (e.g. cytopenia, ascites, malabsorption, or 
osteolytic skeletal lesions) result from organ dysfunction due to mast cell infiltration. In the 
entire ASM subgroup (6/6; 100%), bone marrow biopsy was requested due to either anaemia 
with or without thrombocytopenia or hepatosplenomegaly with or without constitutional 
symptoms [55]. All ASM patients presented with at least one C finding, as defined by the 
2008 WHO criteria (marked cytopenia, osteolysis with or without pathologic fractures, ascites 
and elevated liver enzymes, malabsorption with hypalbuminaemia, palpable splenomegaly 
with hypersplenism). 
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In the SM-AHNMD subgroup, mainly symptoms of the associated neoplasm indicated 
bone marrow biopsy. In most patients (14/15; 93%), these were symptoms of pancytopenia, 
anaemia, leukocytosis, thrombocytosis, bone pain/lesion, or hepatosplenomegaly while in one 
case, the associated SM was revealed by concurrent lymphoma staging process. Regarding 
associated clonal diseases, our findings were consistent with previous reports [27]. Also in our 
study, primarily myeloid neoplasms were identified (12/15; 80%) while lymphoid neoplasms 
were much less frequently detected (3/15; 20%). As provided in current literature [46], we 
found ISM to be mainly accompanied by cutaneous symptoms (8/14; 57%); however, we 
observed a lower rate of this association in ASM (2/6; 33%) and the lack of such 
manifestation in SM-AHNMD. 
Most of the adult patients with mastocytosis, regardless of disease subtype, are 
positive for the somatic activating mutation of the oncogenic receptor tyrosine kinase KIT 
(exon 17, D816V) [33, 42-45] The KIT D816V mutation, which is found in up to 85% of all 
SM patients, is of both pathogenetic and diagnostic relevance [26, 43-45]. 
In our SM patient population, C-KIT mutations detected by PCR were confirmed by Sanger 
sequencing. Out of all detected cases, only those were enrolled in the SM study which strictly 
met the relevant 2008 WHO criteria (major criterion and ≥1 minor criterion, OR ≥3 minor 
criteria). In accordance with literature data, KIT D816V mutation positivity was detected in 
78% (11/14) of ISM patients, 80% (12/15) of AHNMD patients, and 83% (5/6) of ASM 
patients, respectively [31, 96]. 
The clinical presentation of SM is highly heterogeneous ranging from asymptomatic 
manifestations (ISM) to severe, progressive disease forms greatly affecting life expectancy 
(ASM, MCL) [31]. The correct diagnosis is therefore of crucial importance, combining the 
analysis of histopathological and molecular characteristics with the assessment of B and C 
findings. The complex evaluation of these parameters will determine which WHO 
subcategory each patient is to be assigned to. The updated 2008 WHO nomenclature with its 
strong prognostic implications provides a much better prediction of the typical clinical course 
and the expected survival in each SM subtype. A long-term Spanish study revealed that the 
great majority of adult ISM patients are able to live a normal life [97]. 
The results of the ever largest trial to confirm the prognostic value of the current WHO 
classification system were published in 2009 [27]. Within this study, clinical, laboratory, and 
survival data of 342 adult patients diagnosed with SM over a 30-year-long period were 
recorded and evaluated. Compared to the non-indolent forms of SM (AHNMD and ASM), the 
life expectancy in the ISM group was considerably higher and not significantly different from 
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the age- and sex-matched American (USA) population for the appropriate time period, based 
on the date of diagnosis [27]. 
The aim of our research was to analyse the set of adult SM cases emerged in a cohesive 
geographic region of Hungary. The distribution of SM subtypes in our study population of 
35 patients was mostly similar to that reported in the largest clinical trial in SM with the 
updated WHO criteria: ISM 14/35 (40%), SM-AHNMD 15/35 (42%), ASM 6/35 (17%) and 
MCL 0%, vs. 46%, 40%, 12%, and 1%, respectively [27, 50]. 
Our analyses on Hungarian patients revealed that the survival in SM (including all subtypes) 
is worse than that expected in the age- and sex-matched Hungarian population. The life 
expectancy of patients with ISM was excellent whereas SM-AHNMD and ASM groups had a 
reduced median survival. The distribution of subtypes and the survival pattern seen in our SM 
study population was similar to that previously reported in the Mayo Clinic trial [27, 50]. 
To date, only limited epidemiologic data are available in SM. The prevalence of 
mastocytosis in Central Europe is estimated at 0.5-1/10,000 [37]. Local/regional data on ISM 
have been reported from The Netherlands (Groningen) and population-based epidemiological 
data from Denmark [36, 38, 39]. Moreover, the recently established centralized ECNM 
registry is still collecting data from ten European countries; therefore, epidemiological data on 
the prevalence of SM are already available [36]. We found the 13-year cumulative incidence 
of SM in the general population aged 15 years or more amounts to 0.27/10,000 which meets 
the criterion of orphan diseases. As in the most relevant literature [37], we could not report a 
gender predominance. Our data on the cumulative incidence of SM are the first such results 
published in Hungary. Since only cases that strictly complied with the WHO criteria were 
included in our SM investigations, the cumulative incidence of SM calculated during our 
research is likely to be somewhat underestimated. Patients with skin lesions who refused bone 
marrow biopsy were not enrolled in our analyses. The real cumulative incidence might be 
higher because SM is often underdiagnosed due to its subtle or even absent symptoms. 
Within the SM cohort, we individually reported the course of a female patient with 
ISM followed-up for 27 years, an unusual case of particular clinical relevance [54]. During 
this uniquely long follow-up, she experienced recurrent specific cutaneous symptoms which 
greatly impaired her quality of life. As her cutaneous symptomes showed only slight and 
temporary improvement on multiple symptomatic treatments (antihistamine, sodium 
cromoglicate, psoralen + ultraviolet A light [PUVA] therapy, IFN-alpha), imatinib mesylate 
was introduced even though neither imatinib-resistant KIT D816V nor any imatinib-sensitive 
KIT mutation was identified. Unexpectedly, the patient with this KIT D816V mutation-
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negative disease achieved a considerable reduction of skin lesions and a temporary 
appreciable improvement of her quality of life on imatinib. 
Currently, there is no curative treatment for SM. The available therapies (including 
histamine receptor antagonists and other antimediator agents) give only symptomatic relief by 
decreasing the effects of mast cell activation. An important component of SM treatment is the 
elimination of known symptom triggers. The perioperative management of SM patients is 
particularly difficult: a multidisciplinary preoperative assessment, an adequate premedication, 
and a close intra- and postoperative monitoring are of outstanding importantance [28]. 
Cytoreductive and targeted therapies (tyrosine-kinase inhibitors) can only be considered in 
aggressive and leukaemic SM variants. As the vast majority of SM cases harbour the known 
imatinib-resistant KIT D816V mutation, currently available tyrosine-kinase inhibitors are, 
unfortunately, ineffective. Other drugs like multikinase inhibitors are still under clinical 
investigation. The prognosis of these patients remains poor, even if treated with novel Kit-
targeting agents, polychemotherapy, or HSC transplantation [26]. 
4.3 HYPEREOSINOPHILIC SYNDROME 
Cardiac manifestations are the major cause of morbidity in HES and develop in three 
stages. The first acute, mostly asymptomatic necrotic stage is due to eosinophilic infiltration 
of the myocardium. The initial damage is thought to be mediated by the contents of the 
eosinophilic granules. The intermediate (thrombotic) phase is characterized by thrombus 
formation followed by thrombus organization into a thick layer of granulation tissue. In the 
third, fibrotic stage, granulation tissue evolves into fibrosis with a small inflammatory zone. 
Nowadays, the term “Loeffler’s endomyocarditis” is used to describe the thrombotic and 
fibrotic stage of cardiac involvement in HES. Typical echocardiographic findings include 
endocardial thickening, fibrothrombotic obliteration of the ventricular apices, and valvular 
regurgitation due to restricted motion of the posterior mitral leaflet as assessed by routine 2D 
Doppler echocardiography. At enrolment, the majority of our HES patients did not have any 
known cardiovascular disease (except for Case 5) or clinical signs of thrombosis/fibrosis 
characteristic of Loeffler’s endocarditis. They represented theoretically the first –
 asymptomatic – stage of the disease; therefore, any subsequent alteration in LA morphology 
and function could be attributed solely to HES. Only LV hypertrophy and dilated LA could be 
detected by conventional 2D Doppler echocardiography without significant valvular 
regurgitations or thrombus formation. 3DSTE confirmed LA volumetric changes in all phases 
of LA function and found alterations in both global and mean peak segmental LA-CS, 
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suggesting a reduced LA reservoir function and remodelling. Wide spectrum of 
pathophysiological changes could lead to LA remodelling with structural, functional, or 
neurohormonal etc. consequences. The real mechanism behind LA remodelling in HES is not 
completely known, but myocyte necrosis, alterations of the extracellular matrix and in the 
release of atrial hormones due to toxic proteins from degranulating eosinophils, and diastolic 
dysfunction could explain our findings. 
3DSTE is a new clinical tool for non-invasive 3D cardiac chamber quantification of 
the LV and LA. The technique is based on the so-called “block-matching algorithm” of the 
myocardial speckles during their frame-to-frame motion. 3DSTE has been demonstrated to be 
useful for LA volumetric and strain assessments, allowing more detailed evaluation of LA 
function from the same 3D dataset. Different patterns in 3DSTE-derived volume-based and 
strain functional properties could be demonstrated in different disorders. In a recent 3DSTE 
study, peak LA-RS and LA-LS were found to be altered in hypertrophic cardiomyopathy 
along with preserved LA-CS. In another study, all strains at all LA levels showed alterations 
in atrial fibrillation by 3DSTE. In the present study, only peak LA-CS was decreased while 
RS and LS remained unchanged in HES patients. The pathomechanism of this phenomenon, 
i.e. only LA-CS showed alterations in HES is unknown, but haemodynamic factors and their 
relationship with LA fiber orientation could not be excluded, in addition to the above 
processes [7-9, 79-81]. 
Our investigations were the first in HES with 3DSTE. Moreover, it is important to 
emphasize that our research identified an uncommon case. Due to its unique nature and 
potential clinical relevance, we demonstrated it in a separate case report, providing therefore 
an additional proof of the complexity of HES. The patient with hyperosinophilia in our report 
[86] had involvement of the CNS and the myocardium. After the onset of neuropsychiatric 
symptoms, magnetic resonance imaging indicated bilateral cerebral and cerebellar cortical-
subcortical lesions involving the watershed areas, mainly in the parieto-occipital regions. The 
first transthoracal echocardiography (TTE) during the presence of neurological symptoms did 
not reveal any pathological findings, but repeated TTE two weeks later suggested the 
involvement of the myocardium in the form of Loeffler’s endocarditis. Abdominal 
ultrasonography showed splenomegaly. Clinical data and bone marrow histopathology 
confirmed the diagnosis of HES. No chromosomal aberration was detected, and subsequent 
molecular tests by FISH demonstrated FIP1L1–PDGFRA gene rearrangement. High-dose 
intravenous steroid (methylprednisolone 500 mg/day) alleviated the neurological symptoms 
within a few weeks while low-dose imatinib (200 mg/day) resulted in an impressive 
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regression of hypereosinophilia and splenomegaly in 6 weeks. The pathogenesis of the 
neurological dysfunction in HES is potentially explained by a number of hypotheses: a) direct 
infiltration of eosinophil cells; b) neurotoxic effect of major basic protein and eosinophil 
cationic protein released from eosinophilic granules; c) local thrombosis due to eosinophil-
induced endothelial dysfunction; or d) brain infarction caused by microembolization from 
endomyocardial fibrosis [98-100]. During follow-up, the patient continued to receive imatinib 
and experienced persistent remission in a stable condition without developing any new 
complaints. The diagnostic work-up requires a close and effective multidisciplinary 
co-operation between the neurologist, the neuroradiologist, cardiologist and the haematologist 
in order to achieve an early and accurate diagnosis and the successful management of a 
patient with a FIP1L1–PDGFRA-positive myeloid neoplasm. 
For patients with strictly defined HES (i.e., after the exclusion of any possible cause of 
a secondary hypereosinophilia), basic therapy consists of corticosteroids, with or without 
hydroxyurea, for the rapid reduction of AEC. For steroid non-responders, hydroxyurea may 
be administered alone. IFN-alpha can induce both haematological and cytogenetic remission 
in HES and CEL patients refractory to prior therapies. Currently, anti-interleukin-5 or 
anti-CD52 monoclonal antibody treatment is mainly used as experimental therapy in patients 
with PDGFRA/B-negative HES. Treatment choice may vary substantially depending on the 
underlying eosinophilic condition (whether a targeted molecular therapy is considered or not) 
and the extent of organ damage. 
5 SUMMARY 
CONCLUSIONS AND CLINICAL IMPLICATIONS OF OUR RESEARCH 
For purposes of our research focussing especially on Ph-negative MPNs, we 
retrospectively established a database of PV, SM, and HES cases diagnosed at the 
2nd Department of Internal Medicine and Cardiology Centre between 1998 and 2014. The 
collected data were analyzed and assessed by disease-relevant factors and in accordance with 
literature requirements. 
5.1 POLYCYTHAEMIA VERA 
In PV, the most common type of Ph-negative MPDs our research focussed on vascular 
complications. Vascular events represent the primary cause of morbidity and mortality in PV 
and require therefore a strong multidisciplinary approach in their diagnosis and treatment. 
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· The number of major thrombotic events in PV patients that occurred prior to (30.32%) 
or during the follow-up (14.83%) was evaluated retrospectively. 
· We conducted a separate analysis and evaluation of each and every CV and 
cerebrovascular event which are usually presented as aggregate data in large-scale 
trials. 
· Regarding cerebrovascular complications in PV, the majority of cerebrovascular 
complications were chronic ischaemic white matter lesions in our cohort of PV 
patients. Mild cerebral atrophy was also a frequent finding. The clinical presentation 
of cerebrovascular events was predominated by lacunar syndromes or VBI. Most of 
the patients presented at least two serious conventional vascular risk factors, which 
were supposed to have an impact on both the clinical course of the disease and the 
morphological alterations seen on brain imaging. These findings suggest that PV 
predisposes to small vessel cerebral disease manifested primarily as lacunar 
syndromes, despite the simultaneous presence of additional vascular risk factors in 
most patients. 
· Regarding CV complications, NSTEMI was observed. Most patients had at least two 
conventional vascular risk factors. Our findings led us to suppose that the early 
diagnosis followed by percutaneous coronary intervention and an aggressive and 
personalized management of CV risk factors may be effective in the prevention of 
subsequent vascular events. The importance of a close co-operation between the 
haematologist and specialists in the field of vascular medicine is emphasized. 
· The contribution of CV risk factors as newly hypothesized additional risk factors to 
subsequent thrombotic complications in PV was demonstrated in our patient 
population. Our findings clearly indicate the importance of the identification and 
consideration of these risk factors in a more accurate and individualized risk-guided 
thrombosis management in PV. 
5.2 SYSTEMIC MASTOCYTOSIS 
Analyses in our SM patient group were driven by the orphan nature and the diagnostic, 
therapeutic, and prognostic difficulties usually seen in this condition. The multidisciplinary 
significance of SM lies in its challenging diagnostic aspects and characteristic multi-organ 
nature. 
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· As part of our research, we analyzed bone marrow histological features, molecular 
characteristics, and laboratory and clinical parameters at presentation in a large cohort 
of SM patients. 
· The frequency of KIT D816V mutation in our study population was evaluated by SM 
subtype. The established occurrence of this particular mutation and its impact on the 
clinicohaematological findings was compliant with general literature data. 
· Life expectancy of SM patients was compared to age- and sex-matched controls. In 
addition, the prognostic relevance of the 2008 WHO classification of SM in the 
investigated patient population was evaluated. Our analyses on Hungarian patients 
revealed that the survival in SM (including all subtypes) is worse than that expected in 
the age- and sex-matched Hungarian population. The life expectancy of patients with 
ISM was excellent whereas SM-AHNMD and ASM groups had a reduced median 
survival. The distribution of subtypes and the survival pattern seen in our SM study 
population was similar to that reported in the largest trial previously published. 
· Epidemiological data on SM, an orphan Ph-negative MPN are only sparsely available 
in the literature. With our research, we provided important new data on SM and 
quantified its cumulative incidence in the South Great Plain region of Hungary. 
5.3 HYPEREOSINOPHILIC SYNDROME 
HES is a particularly heterogeneous entity with a wide range of clinical manifestations and a 
typically multi-organ presentation, facilitating a multidisciplinary thinking in its management 
· We first performed investigations with 3DSTE, a novel non-invasive cardiac 
diagnostic tool in patients with HES. All HES patients and their age- and sex-matched 
healthy controls underwent complete 2D Doppler echocardiography and 3DSTE. 
· On 3DSTE, increased LA volumes and LA-SVs were demonstrated in HES patients, 
accompanied by reduced LA-CS values. These findings suggest a structural and 
functional LA remodelling in the evaluated patients. The diagnostic work-up requires a 
close and effective multidisciplinary co-operation between the cardiologist, 
neurologist, the neuroradiologist, and the haematologist in order to achieve an early 
and precise diagnosis and a successful management of cases with hypereosinophilic 
syndrome. 
The diagnosis and treatment of all three investigated Ph-negative MPDs is highly complex, 
calling for a multidisciplinary collaboration among several clinical and non-clinical divisions. 
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